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Immunotherapy has recently garnered plenty of attention to improve the clinical outcomes in the 
treatment of various diseases. However, owing to the dynamic nature of the immune system, this 
approach has often been challenged by concerns regarding the lack of adequate long-term 
responses in patients. The development of microneedles (MNs) has resulted in the improvement 
and expansion of immuno-reprogramming strategies due to the housing of high accumulation of 
dendritic cells, macrophages, lymphocytes, and mast cells in the dermis layer of the skin. In 
addition, MNs possess many outstanding properties, such as the ability for the painless traverse 
of the stratum corneum, minimal invasiveness, facile fabrication, excellent biocompatibility, 
convenient administration, and bypassing first-pass metabolism that allows direct translocation 
of therapeutics into the systematic circulation. These advantages make MNs excellent candidates 
for the delivery of immunological biomolecules to the dermal antigen-presenting cells in the skin 
with the aim of vaccinating or treating different diseases, such as cancer and autoimmune 
disorders, with minimal invasiveness and side effects. This review discusses the recent advances 















Microneedles (MNs) are needle-like structures with microscale diameter and lengths up to 1 mm 
that can penetrate into the stratum corneum (10–40 µm in thickness), and enter the 
epidermis/dermis layers without touching blood vessels and pain-sensing neurons, while the 
administration is easy enough to avoid the need for professional training [1-3]. Therefore, MNs 
have garnered great attention for transdermal immunotherapy since they can bypass the stratum 
corneum layer and directly deliver antibodies, allergens, and therapeutic antigens into the skin, 
painless and with minimal invasiveness [4, 5]. All types of MNs can promote the delivery of 
immunostimulatory or immunosuppressive payloads into the immune cell-rich 
microenvironment of the dermis layer [6, 7], while controlling the dosage and improving the 
consistency of therapeutic response is achievable [8-11].  
Immunotherapy has been proposed as a promising strategy to manage or fight different diseases 
through the activation or suppression of the patient’s immune system [12]. The controlled 
modulation of the immune system is an important issue that should be taken into account during 
the design of novel immune-formulations, in order to achieve desired therapeutic effects without 
off-target responses [13]. For example, in the case of cancer and infectious diseases, 
immunomodulators should activate immune cells and elicit stimulatory responses. In contrast, in 
the context of allergies, autoimmune disorders, transplantation, and wound healing, 
immunomodulators are applied to hinder the activation of immune cells in hyperactive biological 
environments to accelerate treatment or tissue regeneration [14, 15]. Therefore, immunotherapy 
can be achieved by various approaches, including immune-modifying agents (e.g., cytokines and 
vaccines), oncolytic viruses, adoptive cell therapy, immune checkpoint inhibitors, etc. [16, 17]. 













antibodies, and immune cells in patients to trigger anti-tumor action without generating 
immunological memory, or active immunotherapy by triggering the immune system of the 
patient to create a long-lasting antigen-specific response. Nevertheless, there are still significant 
limitations to overcome, such as off-target toxicity, tissue heterogeneity, and insufficient 
durability, demonstrating the necessity for further investigations of advanced immunotherapeutic 
formulations due to the unpredictable efficacy, weak immunogenicity, and reduced tissue 
infiltration of the current formulations [18]. The successful implementation of immunotherapies 
and breakthroughs in clinical practice by new techniques and formulations depends on an 
adequate dose of immunomodulators, suitable delivery technique, and the right location of their 
infusion [19, 20]. It is well-known that both the antigen type and the route by which antibodies, 
therapeutic antigens, and allergens are delivered to the desired region strongly influence the 
resulting immune response [21]. For example, the initiation of a T-helper 2 (Th2)-based immune 
response against the allergen results in the maintenance or exacerbation of allergic inflammation 
in patients. In contrast, initiation of a Th1 type immune response against the allergen and viruses 
might create beneficial effects [22, 23].  
In this review, we discuss the recent progress in the development of MNs for immunotherapy of 
hard-to-treat and chronic diseases to achieve the highest efficiency with minimal side effects. 
First, we discuss recent advancements of MNs for immunotherapy of cancer, followed by 
autoimmune diseases, allergies, inflammatory diseases, as well as discussing vaccination against 
viral and bacterial diseases (Scheme 1). We summarize the outlooks on the trajectory of recent 

















Scheme 1. Different strategies employed by MNs to treat or vaccinate various immune-related 
diseases. 
 
2. Physicochemical features of materials used in immunotherapeutic MNs  
Various types of materials have received substantial attention for MN design to induce 
programmed immune responses by contributing to sustained release of immunotherapeutic 













Moreover, using biomaterials within the structure of MNs can trigger a series of pathways for 
recruitment or reprogramming of immune cells, which results in more localized immune 
responses in comparison with systemic methods [25].  Successful immunotherapy by MNs 
strongly depends on the physiochemical properties of materials that are used to fabricate these 
needles. The most common materials include silicon [26, 27], metals [28, 29], glasses [30], 
ceramics [31], and polymers [32], which their mechanical strength, porosity, charge, and 
molecular weight can highly affect antigen stability, antigen or vaccine loading into the MNs or 
even control the kinetics of vaccine transportation in vivo [33].  For example, Kathuria et al. 
showed that the dissolution rate of polyvinylpyrrolidone (PVP)-based dissolvable MN patches 
can be tuned by the incorporation of hydroxypropyl methylcellulose (HPMC) and 
methylcellulose (MC) with different molecular weights as dissolution modifier [34]. The PVP 
MNs showed a rapid dissolution profile within 0.75 h, while incorporating HPMC with high 
molecular weight (K100LV, or K100M) into their structure resulted in dissolution profiles 
ranging from 2-2.5 h. Likewise, incorporating low molecular weight HPMCs (E3LV, or E15LV) 
into the structure of the PVP MNs resulted in dissolution time of  higher than 16 h. 
Moreover, fabrication methods of MNs can strongly affect the cost-effectiveness of 
immunotherapy.  For example, although micromolding is the most common fabrication 
technique for dissolving MNs,  its efficiency for immunotherapy has been often challenged by 
concerns regarding noticeable antigen wastage in this method and lack of cost-saving for 
manufacturers [35]. In addition, the selection of a suitable material that contributes to the 
localization of antigen within the needles is a substantial issue that needs much attention to 
optimize immunotherapy of various diseases by MNs. For example, Prausnitz et al. improved the 













polymer solution that was able to increase viscosity or contribute to the incorporation of an air 
bubble at the base of the MN to hamper diffusion of therapeutic molecules into the backing [36]. 
A summary of materials used in the structure of MNs towards immunotherapy, as well as a 














Table 1. A summary of various materials used into the structure of MNs towards 
immunotherapy, as well as a comparison of their advantages and limitations.  









Silicon Wet etch technology - Ability for coating of the 
viable virus in a dry form 
around the shaft of needles 












Silicon Wet etch technology - Successful delivery of 
liquid vaccinia virus Ankara 
(MVA) vaccine 





Silicon Wet etch technology Decreasing the anti-vector 
antibody response 
------ [39] 




al systems (MEMS) 
Easily fabrication using 
existing MEMS technologies 





 Silicon  
----- 
- Capability of surface 
decoration of  silicon with 
pH-sensitive groups towards 





antigen ( no for all 
the antigens) 
[41] 
 Silicon ------ ------ -Lack of FDA 


















penetration into the skin 
Possibility of 





           ---------- Capability for creating the 
nano-patterning on the 





agents owing to 
low hydrophilic 







Laser cutting Cost-effective and FDA 
approval for stainless MNs 













 Titanium Lithographic masking 
followed by wet 
etching 
Facile adsorption of 
Vaccine to the titanium 
surface via 
electrostatic/hydrophobic 
interactions due to high 
dielectric constant (ε ~ 114) 
and isoelectric point ( 
3.5–6.7) of titanium oxide 





Micromolding process Higher mechanical strength 
and better stability at high 
temperature and humidity 






















Micromolding process Capability for controlling 
drug release by changing the 
bulk surface area, porosity 
and resorbability of the 
ceramics 





Al2O3 Micromolding process Capability for creating 
nanoporous MNs for both 
delivery of substances, and 
the extraction of compounds 
---- [48] 









- Good in vivo resorbability 
(micromolding process) 
- Adjustable porosity 
Non-resorbability 
of sintered ceramic 
MNs 
[49] 
 Alumina - Sintering 
technique 

















Soft lithography Highly water solubility, high 
tensile strength, and FDA 
approval of PVP 
----- [51] 
 PVP Micromolding process  safely clearance of PVP via 
the kidneys within a few 
days 
---- [52] 
 PVP Micromolding process  Low likelihood of RNase 
contamination of PVP 
-Poor solubility of 
















- Inhibitory effect 
of concentrated 
PVP solutions on 
mRNA transfection 
due to steric 
hindrance. 
 PVP In situ micromolding 
process 
Good mechanical strength of 
PVP due to the presence of a 
ring in the chemical 
backbone structure of the 











 PVP/ dextran two-step molding 
process 
the adjuvant effects of PVP 
and dextran 
----- [55] 










into them during 
MN preparation 
[56] 
 chitosan Micromolding process - Excellent biodegradability 
- Noncytotoxicity 
- Ability of chitosan for 
improving both humoral and 
cell-mediated immune 
responses 
- creating  an antigen depot 










 Gantrez Micromolding process Highly water solubility and  










------- The difficulty of  
analysis of the 













 - FDA approval for both 
trehalose and CMC 
- Increasing antigen stability 
by trehalose 
- water-solubility and 














 CMC and 
amylopectin 




strength at high 






- Adjuvant properties of 
sodium alginate 
- Good biocompatibility 
and biodegradability 
- Utilizing  sodium alginate 








glycolic acid MN 
[63] 
 Silk fibroin 
/poly(acryli 
c acid) 
Micromolding process - Good 
Biocompatibility and 
Biodegradability of silk 
fibroin 
- Simple one-step process for 
loading antigens in silk 
protein matrices 
- Facile stabilization of 
immunotherapeutic agents 
and vaccines in silk at room 
temperature for more than 
two months 
- Rapid dissolution of PPA 
in the skin 
- Sustained vaccine release 
from silk protein matrices 
(over 1–2 weeks) 
- The high 








Micromolding process - Rapid dissolution of 
PPA in the skin 
- Adjustable sustained 
release of encapsulated 
vaccines based on the PLGA 
molecular weight 
- Complexity of 
the vaccine loading 








Dip-coating - Improving antigen stability 
during drying by trehalose 
disaccharide 
- Improving the retention of 
Hemagglutination activity of 
influenza vaccine after 
drying by trehalose 
Loss of 
Hemagglutination 
(HA) activity at 
high concentrations 






































Dip-coating Reducing virus aggregation 
at 3% concentration of 
trehalose 
Reduced delivery 
efficiency of the 





















Layer by layer 
assembly 
 
- Ability for the preparation 
of bioresponsive MNs due to 
photo-sensitive and pH-
responsive properties of 
PNMP polymer 
- Delivery of antigens in a 
sustained manner after 
photoswitching PNMP 
polymer through ultraviolet 




for 15 min during coating 







3. Trend of material development in the clinical trials of MN technology 
MNs are still under development for the translation of immunotherapeutic molecules into the 
clinical trial phase. The solid and hollow MNs fabricated from silicon and metals have 
dominated the clinical trial setup for transportation of immunotherapeutic molecules [68, 69]. 
Although coated silicon MNs were used for the first time to create immunization, most of MNs 





, hollow MNs device made of silicon, are the two most widely used MN 
devices for intradermal vaccine delivery in clinical trials [2]. In a clinical trial study by Icardi et 
al., intradermal vaccine delivery using Soluvia
TM
 microinjection system in children, adults <60 
years, and elderly people demonstrated well tolerability without safety issues [70]. Likewise, 
using MicronJet
TM
 for the delivery of inactivated polio vaccine (IPV) to in 6–14 week-old infants 













decreasing in antibody titers was found after using MicronJetTM injection in human 
immunodeficiency virus (HIV)-infected patients compared to intramuscular (IM) injection [72]. 
Although above-mentioned studies show that silicon or metal MNs might possess beneficial 
effects on clinical trial outcomes, their clinical translation has been often challenged by concerns 
regarding lack of FDA approval for silicon and producing biohazardous sharp wastes by metals 
[73]. Currently, polymers are accelerating into the clinic for MN fabrication due to increasing 
interest in biocompatible systems [74]. Phase 1 of the clinical trial studies have shown that using 
biocompatible and dissolvable polymeric MNs for influenza vaccination was well tolerated and 
generated robust antibody responses compared to IM injection [75]. Hirobe et al. reported that 
using a self-dissolving MN (MicroHyala; MH) made of hyaluronic acid (HA) and collagen in 20 
healthy volunteers enrolled in a clinical study effectively increased antibody titer in comparison 
with transcutaneous immunization (TCI) without any severe adverse reactions [76][77]. 
Likewise, a clinical trials study showed that dissolvable polymeric MNs composed of 50% (w/w) 
polyvinyl alcohol (molecular weight 31 kDa) and 50% (w/w) sucrose did not create pain or 
swelling in the skin, and only mild erythema localized to the injection site was found after 
administration [78]. Considering the above examples, we estimate that in the near future we will 
observe a high interest in the design and fabrication of biocompatible and dissolvable polymeric 
MN systems for immunotherapeutic applications.  
 
4. Cancer immunotherapy by MN patches 
Various types of MNs, including solid removable, coated, dissolving, hollow, and hydrogel-













drawbacks of cancer immunotherapy by other approaches that have hindered their clinical 
translation.  
 
Figure 1. Different types of MNs used for the delivery of immunotherapeutic agents and 
mechanisms of action for the controlled release of payloads. Solid MNs: immunotherapeutic 
agents are able to pass via the micro-channels created by MN. Coated MNs: immunotherapeutic 
agents are able to mix with interstitial fluids and then their delivery occurs through diffusion. 
Dissolving MNs: dissolution and diffusion of immunotherapeutic agents occur into the body 
along with other components within the structure of MNs. Hollow MNs: immunotherapeutic 
agents are able to pass through the MNs. Hydrogel-forming MNs: immunotherapeutic agents are 
able to diffuse into the body after insertion and the swelling of MNs. Adapted with permission 














In general, current limitations include inadequate infiltration of lymphocytes during the evolution 
of tumoral immune escape, the presence of immune checkpoints in the tumor site, the high cost 
of immune checkpoint inhibitors, and the possible development of dosage-related autoimmune 
side effects through off-target binding of therapeutic agents to healthy tissues [80-83]. In this 
section, the discussion is subdivided based on the biological pathways and biological molecules 
used for MN-mediated cancer immunotherapy. 
 
4.1. Design of MNs for immune checkpoint inhibition 
Tumor cells possess several mechanisms to conceal themselves as ―healthy cells‖ and prevent 
their detection and digestion by the immune system. These mechanisms have been summarized 
in the review by Liu et al.[84].  Although immune checkpoint molecules display powerful roles 
in the prevention of autoimmunity and tissue damage following the immune reaction in the 
pathogenic infection, dysregulating their expression in cancer tissue results in innate- and 
adaptive immune resistance of tumor [85]. Generally, the programmed cell death protein 1 
(PD1), indoleamine 2,3-dioxygenase (IDO), and the cytotoxic T-lymphocyte-associated antigen 
4 (CTLA4) are the three most important immune checkpoint molecules that are involved in the 
regulation of T-cell function and are extensively used to modulate antitumor immunity [86].  
 
4.1.1. Design of MNs for cancer immunotherapy by IDO blockade 
IDO is an enzyme with the ability to degrade essential amino acid, tryptophan, in an independent 
process of normal tryptophan homeostasis. IDO is highly expressed in both tumor cells and 
stromal cells and contributes to the establishment of peripheral tolerance to tumor antigens. IDO 













survival and outgrowth through the creation of pathogenic inflammatory states [87]. Although 
photothermal therapy (PTT) has been reported to be a promising approach for the treatment of 
metastatic tumors through alteration of immune response with the help of releasing neoantigens 
and damage-associated molecular patterns, the upregulation of IDO by mild heating limits 
effective immunotherapeutic outcome. PTT can increase interferon-γ (IFN-γ) secretion and 
subsequently enhance the IDO expression in tumor cells and antigen-presenting cells (APCs) 
[88]. High expression levels of IDO suppresses APCs activation and decline their antigen-
presenting efficacy [89]. IDO is able to catalyze the degradation of tryptophan into kynurenine, 
which, in turn, gives rise to impairment of CD8
+
 T cells activation and inhibition of their 
antitumor ability via increased activity of regulatory T cells (Tregs) [90, 91]. To address these 
limitations of PPT, Chen et al. engineered an ingenious core-shell structure MN (CSMNs) array 
that was able to synergistically boost robust immune response through intralesional co-delivery 
of a photosensitizer and IDO blocking agent [92]. They loaded 1-methyl-tryptophan (1-MT) into 
the cross-linked PVP and poly (vinyl alcohol) gel as the MN core and encapsulated 
photosensitizer indocyanine green into chitosan nanoparticles (ICG-NPs), followed by 
concentrating on the tip shell of MNs. The in vivo experiments in the lung metastatic tumor 
model showed that treatment with 1-MT@ICG-NPs-MN+L (laser irradiation) resulted in 1.8-
fold higher percentage of CD8
+
 T cells in the primary tumors than blank group (Figure 2A and 
2B). The immunofluorescence staining demonstrated that that treatment with 1-MT@ICG-NPs-
MN+L significantly increased the amount of CD8+ T cells in the lung slices whereas markedly 
reduced the expressions of IFN-γ in the metastatic nodules compared to the blank group (Figure 
2C and 2D). Likewise, H&E staining and terminal deoxynucleotidyl transferase dUTP nick-end 













higher in 1-MT@ICG-NPs-MN+L group as compared to other groups (Figure 2E and 2F). 
Immunohistochemistry staining further confirmed that the anti-metastatic effect of 1-MT@ICG-
NPs-MN+L was associated with significantly reduced levels of IDO enzyme compared to other 
groups (Figure 2G). Generally, the results of this study showed that 1-MT@ICG-NPs-MN+L 
could exert good anti-metastatic effect through the activation of robust immune response in the 
tumor microenvironment (TME) using synergistic immunotherapy. 
 
Figure 2. The immune response of CSMNs on a lung metastatic B16 tumor model. A) Flow 




T cell infiltration in primary tumors. B) Quantitative 
analysis of CD8
+
 T cell infiltration in primary tumors. Immunofluorescence staining of C) CD8+ 
T cells (red) and D) IFN-γ (green) in metastatic lung nodules. E) Histological assessment of 
primary tumors (Scale bar: 400 μm). F) TUNEL staining of the primary tumors (Scale bar: 50 













nodules of the B16 tumors after various treatments (Scale bar: 200 μm). (G1) Blank, (G2) 1-MT-
MN, (G3) ICG-NPs-MN+L, (G4) 1-MT@ICG-NPs-MN+L. L= (laser irradiation) in G3 and G4 
groups (* P<0.05, ** P<0.01, *** P<0.001). Reproduced with permission from ref.[92]; 
Copyright 2020, American Chemical Society. 
 
4.1.2. Design of MNs for cancer immunotherapy by PD-L1 blockade  
The interplay between programmed cell death receptor 1 (PD-1), present on the surface of 
activated anti-tumor cytotoxic T-cells, and PD ligand one (PD-L1), found on the surface of 
tumor cells, results in facilitating tumor immune escape. Indeed, the interaction between PD-1 
and PD-L1 results in the initiation of apoptosis in the tumor-specific cytotoxic T-cell, annealing 
their antitumoral immune effects [93-95]. Immune checkpoint inhibitors against PD-1, such as 
nivolumab, are routinely employed for the treatment of metastatic melanoma [96]. Nevertheless, 
as an expensive therapeutic option, this drug cannot bring optimal results in up to 80% of 
patients due to the presence or development of resistance mechanisms or the instauration of off-
site immunotoxicity derived from the systemic administration of the medicines [96, 97]. To 
address these limitations, a biodegradable MN was designed to target the PD-1 pathway by 
delivering a checkpoint blockade antibody against melanoma locally in the TME [98]. In this 
study, Wang et al. embedded the anti-PD-1 antibodies (aPD1) and glucose oxidase 
(GOx)/catalase (CAT) enzymatic system within pH-sensitive nanoparticles composed of ketal 
modified dextran and then loaded it into HA-based MNs (Figure 3A and 3B) [98]. Various 
microscopic methods (scanning electron microscope (SEM) and fluorescence) confirmed the 
distribution of the loaded pH-sensitive NPs at the tips of the MNs (Figure 3C–3E). In vivo 
experiments demonstrated that the MNs were capable of penetrating the TME to a depth of 
approximately 200 μm (Figure 3F–3H). The MN patch used in this study showed a sustained 













by the CAT enzymatic system: the enzymes convert glucose into gluconic acid, decreasing the 
pH in their immediate surrounding, dissolving the NPs and releasing the antibody. The MN patch 
elicited a robust immune response against B16F10 mouse melanoma in comparison to free aPD1, 
completely eradicating the tumors in some of the animals treated. Their results showed that 
treatment with this aPD1 patch resulted in the survival of 40% of mice after 40 days, while all 
the mice treated with free aPD1 or a MN patch without the CAT enzyme died within 30 days 
after treatment due to tumor relapsing.  
 
Figure 3. Innovative self-degradable MN patch for the sustained and smart release of aPD1 
towards cancer immunotherapy in a B16F10 mouse melanoma model. A) Schematic depiction of 
HA-based MNs loaded with pH-sensitive NPs (ketal modified dextran containing 
aPD1/GOx/CAT) and the fate of NPs at the tumor site after insertion into the skin. The release of 
aPD1 was based on the enzyme-mediated conversion of blood glucose to gluconic acid and 
subsequent gradual dissociation of NPs. B) The blockade of PD-1 by aPD1 and subsequent 
activation of the immune system to fight skin tumor cells. C) SEM image of a MN patch (scale 













sensitive NPs into MNs (scale bar 5 μm). E) Fluorescence imaging of MNs containing FITC-
antibody loaded NPs (scale bar 200 μm). F) Desired region for the insertion of MNs on the 
mouse skin (red dashed line) and proof of effective delivery by trypan blue staining (scale bar 1 
mm). G) H&E stain of mouse skin region penetrated by MN (scale bar 200 μm). H) Merged 
fluorescence and bright field image demonstrating the presence of FITC-antibody loaded MN in 
mouse skin after insertion (green: aPD1) (scale bar 200 μm). Reproduced with permission from 
ref.[98]; Copyright 2016, American Chemical Society.  
 
In another study, a transdermal hollow structured MN array (MNA) patch was designed to 
enable cold atmospheric plasma (CAP)-mediated aPD-L1 therapy [99]. The application of CAP 
improved the transportation of the payload into the TME by the MN patch. Furthermore, CAP 
was channeled to the tumor, inducing the death of cancer cells and the release of tumor-
associated antigens, which resulted in the significant maturation of dendritic cells (DCs) and 
presentation of the antigens to T-cells in the draining lymph nodes. The release of tumor-
associated antigens combined with the simultaneous release of aPD-L1 antibody controlled the 
tumor growth in both primary tumors and distant tumors, demonstrating the effective priming of 
a systemic antitumoral immune response.  Since the therapeutic potential of various approaches 
might be undermined due to the diversity, complexity, and heterogeneity of tumors, MNs can 
provide a paradigm shift for combination therapy to enhance treatment efficacy [100]. For 
example, Yanqi et al. developed a transcutaneous delivery platform for aPD1. The technology 
combined nanocapsules of HA modified with 1-MT, an inhibitor of IDO, embedded within MNs 
[101]. The IDO enzyme is responsible for maintaining DCs in an immature state, suppressing 
antigen-specific T cell proliferation by increasing their sensitivity to apoptosis [102]. 
Furthermore, this enzyme has been correlated with an increased number of anti-inflammatory 
Tregs [103]. The TME is characterized by the overexpression of hyaluronidase, which controls 
the release of aPD1 through the enzymatic digestion of HA-based MNs. In vivo experiments on a 
B16.F10 mouse model of melanoma showed that the MNs induced a significant increase in the 
amount of T-cell, and, in particular, in CD8
+













Tregs in the TME. However, the authors did not evaluate whether the increased presence of 
cytotoxic T-cells is correlated with an increase in the number of antigen-specific cytotoxic T-
cells.  
Despite all the advantages of MNs as innovative formulations, they suffer from several 
disadvantages towards the effective delivery of immune checkpoint inhibitors. The limitations 
include low drug loading capacity owing to the small volume of their microstructures and the 
inability of simultaneous multi-drug loading due to the specific interaction of drug-matrix [104, 
105]. To overcome some of these disadvantages, Yang et al. fabricated a highly drug-
concentrated hybrid core-shell MN (CSMN) system to facilitate the co-delivery of checkpoint 
inhibitors, 1-MT and aPD-L1, into the TME (Figure 4A and 4B) [106]. The author firstly 
synthesized the shell of CSMN by pipetting sodium alginate and chitosan solution onto the 
surface of a polydimethylsiloxane (PDMS) mold, followed by the addition of aPD-L1. In the 
next step, an aqueous solution containing 25% (w/v) PVP K30 with 15 mg/mL 1-MT and 15% 
(w/v) PVA was added on the surface of the molds to create the core (Figure 4C). This fabrication 
method resulted in the concentration of aPD-L1 in the tips of MNs and increased protein loading, 
which was mainly attributed to electrostatic interactions between polymers and proteins and to 
hydrogen-bond interaction between 1-MT and the polymeric matrix of MN. The developed patch 
possessed adequate mechanical strength to penetrate into the corium layer of rat skin to the depth 
of 700 μm (Figure 4D). In vitro experiments showed a complete release of the cargo and the 
degradation of chitosan shell after 48 h. Additionally, in vivo experiments in a B16 subcutaneous 
melanoma mice model demonstrated that the CSMN system better inhibited the tumor growth, 
owing to the longer local retention time of inhibitors compared to the intra-tumor injection route. 

















found in the tumor site of mice treated with the aPD-L1/1-MT CS-CSMN in comparison with 
blank CS-CSMN control (Figure 4E and 4F). 
 
Figure 4. A highly drug-concentrated hybrid CSMN system for co-delivery of checkpoint 
inhibitors, including 1-MT and aPD-L1 and cancer immunotherapy in a B16 subcutaneous 
melanoma mice model. A) Schematic representation of CSMN-assisted co-delivery of aPD-L1 
and 1-MT for the treatment of melanoma. B) A representative photograph of the CS-CSMN 
patch. C) Bright-field image of CS-CSMN (scale bar 500 μm). D) H&E staining image of rat 





 T cells per 10,000 of cells in tumor tissue after the removal of red blood cells 
at12 days after treatment. Data are expressed as Mean ±SD (n = 3 animals per group). ** P<0.0 
and *** P<0.001 versus the aPD-L1/1-MT CS-CSMN group. Reproduced with permission from 














In another interesting example, Lan et al. developed a MN patch loaded with pH-responsive 
tumor-targeted lipid NPs, which provide the possibility of local delivery of aPD-1 and cisplatin 
(CDDP) to create a synergistic immuno-chemotherapy [107]. They firstly synthesized the aPD-
1/CDDP@NPs using a reverse-phase microemulsion technique. Then, aPD-1/CDDP@NPs were 
further encapsulated into dissolving MNs made of PVP using the molding method (Figure 5A). 
Lipid coated NPs were able to facilitate drug release and tumor-targeting. The in vivo 
experiments showed that MN group cause the most notable tumor regression (strongest effect on 
reducing tumor volume and tumor weight) in comparison with PBS, aPD-1, aPD1 + CDDP, and 
aPD-1/CDDP@NPs groups (Figure 5B and 5C). Additionally, the authors investigated body 
weight loss, the blood urea nitrogen (BUN) value, and total immunoglobulin G (IgG) value in the 
serum to assess the systemic toxicity and side effects of engineered MNs. Their results showed 
that the BUN values in all the MN patch groups were within the normal range (Figure 5D). 
Likewise, IgG values were markedly increased in the aPD-1/CDDP@NP MNs group compared 
to other groups (Figure 5E). Histopathological assessments using H&E staining indicated that the 
CDDP group and the aPD-1 plus CDDP group exhibited severe toxic tubular necrosis (the 
glomeruli and Bowman’s capsule collapsing), while no evidence of renal damage was seen in 













Figure 5. MNs loaded with anti-PD-1–cisplatin NPs for synergistic cancer 
immunochemotherapy.  A) Schematic representation of MNs loaded with aPD-1/CDDP@NPs 
towards synergistic cancer immunochemotherapy. The combination of chemotherapy and 
immunotherapy was carried out through encapsulation of aPD-1 and CDDP into NPs and then 
embedding into the MNs. The aPD-1 was able to block the binding of PD-L1 to PD-1 that 
confers the activation of T-cells whereas intracellular release of CDDP facilitated the death of 
tumor cells via inducing direct cytotoxicity to them. B) Tumor volume and (C) tumor weight 
following sacrifice. When the tumor volume reached 10 mm
3
, the treatment of each group was 
started (Three treatments for each group and lasted for three cycles). The measurements of tumor 
volume were performed before the treatment and 3 times after the treatment. D) The BUN value 
and E) total IgG value in the serum. Data were expressed as ± S.D (n = 7 per group). Statistical 
analysis was carried out based on the Mann–Whitney U test (P-value: *p < 0.05, ***p < 0.001). 
Reproduced with permission from ref. [107]; Copyright 2020, The Royal Society of Chemistry. 
 
In another study by Yang et al., a rolling MN electrode array (RoMEA) was engineered to inhibit 
tumor growth in both B16F10 and CT26 xenograft murine models [108]. RoMEA was able to 













through electroporation without any noticeable damage to the skin (Figure 6A). The MN 
electrode array contributed to reducing the pulse voltage by penetrating via high-resistance 
stratum corneum layer. The penetration depth of RoMEA was about 500 µm that was larger than 
the epidermal skin thickness of mice (200 µm), ensuring MN entrance into subcutaneous tissue. 
The researchers employed anti-PD-1 monoclonal antibody or CpG oligodeoxynucleotides 
(CpGODNs) of CpG 2395 (immunoadjuvant) to synergistically improve the antineoplastic 
effects through blocking PD-L1/PD-1 recognition between tumor cells and T cells and increasing 
populations of CD8 
+
 T cells and CD4
+
 T cells.  For combination therapy using siPD-L1 and PD-
1mAb, the antibody was infused into the tumor after siRNA electroporation to synergistically 
block PD-1 on lethal T cells (Figure 6B, parts a and b). In vivo experiments showed that siPD-L1 
without electric pulse stimulation failed to create protective effects and exhibited similar tumor 
growth and survival profiles to PBS, all mice died within two weeks (Figure 6B, parts c-e). 
Although treatment with only anti-PD-1 antibody repressed tumor growth and reduced tumor 
volume, the differences did not reach significant levels, and the survival time was increased to 18 
days. The animals treated with siPD-L1 by RoMEA or in combination with anti-PD-1 antibody 
injection exhibited the highest inhibition of tumor growth, survival profiles, and reducing tumor 













Figure 6. The design of RoMEA MN for combination therapy of tumor through large-area 
nucleic acid delivery (PD-L1-against siRNA (siPD-L1)) and intratumor injection of PD-1 
antibody. A) Schematic representation of RoMEA. (a) Illustration of minimally invasive 













RoMEA device that shows the stainless steel 316 parallel circular blades with MN arrays on edge 
as the electrodes. Two adjacent MN blades connect to the anode (red) and cathode (black), 
respectively. (c) Schematic representation of MN electroporation. (d) Simulation of electric field 
using the RoMEA (50 V). (e) The RoMEA prototype in hand. B) RoMEA-mediated 
immunotherapy in the B16F10 model and its effects on tumor growth and survival profiles. (a) 
Schematic representation of the experiment protocol in a melanoma tumor model in C57BL/6 
mice. (b) Conceptual design of combined immunotherapy approach used in this study. (c and d) 
The tumor growth and survival curves of the mice during the treatment period. (e) 
Representative optical images of the melanoma tumors excised on day 14 post-treatment. 
Information about experimental groups: PBS (control without any treatment), PD-1mAb (mice 
treated with only PD-1mAb), siPD-L1 W/O EP (siPD-L1 without electroporation), siPD-L1 with 
EP (siPD-L1 electroporated with RoMEA), and siPD-L1 with EP & PD-1mAb (siPD-L1 
electroporated with RoMEA plus PD-1 mAb). Data were expressed as the mean ± SEM. * P < 
0.05; ** P < 0.01;*** P < 0.001, **** P < 0.0001 vs the control group. Reproduced with 
permission from ref.[108]; Copyright 2020, Elsevier B.V. 
 
In 2020, Zhou et al. engineered HA MNs loaded with anti-CD40 antibody (DCs targeting 
antibody) and surface decorated by GMS (monostearin)-conjugated HA transfersomes co-
encapsulating poly I:C adjuvant, the tumor-associated antigen (tyrosinase-related protein-2), 
ovalbumin (OVA), and pembrolizumab (anti-PD1 antibody) to improve the maturation of DCs 
and infiltration of effector T cells in tumor-draining lymph node (tdLN) and tumor tissue towards 
synergistic reinforcement of anti-PD1 immunotherapy (Figure 7A) [109]. The authors monitored 
intradermal fluorescence intensity to evaluate the distribution of transfersomes (DiI labeled) in 
vivo. The fluorescence distribution was investigated in lymph nodes, hearts, livers, spleens, and 
kidneys to ascertain tdLNs targeting capacity of transfersomes based nanovaccine- complexed 
MNs. At 48 h after H-αCD40 T(OVA+PolyI:C)/MNs transdermal administration, the DiI 
fluorescence appeared at the lymph node and reached the maximum at 96 h, indicating 
accumulation of the transfersomes in the lymph nodes. Likewise, a gradual increase of the 
fluorescence intensity was found in livers after 96 h. The highest photon quantum intensity was 
seen in lymph nodes (~25 × 104/g; 2-fold higher than livers at 96 h). A significant increase in the 
number of CD4
+
 T or CD8
+













compared to blank MNs (Figure 7B and 7C), indicating that the activation of effector T 
lymphocytes occurred by DCs mediated cascade reactions. Generally, the engineered MNs were 
able to activate DC maturation and improve Th1 immune responses, which, in turn, resulted in 
the inhibition of tumor growth and improving survival profiles.  
 
Figure 7. Combined therapy with nanovaccine complexed MNs with pembrolizumab (αPD1) for 
improving the maturation of DCs and infiltration of effector T cells in tdLN for tumor 
immunotherapy. A) Schematics illustration of modified transfersomes induced immune 
responses in tdLNs through MNs assisted transdermal immunization. Transdermal delivery 
resulted in accumulation in tdLN and surface decoration with αCD40 increased cellular uptake 













into effector T lymphocyte. In the next step, reducing regulatory T lymphocytes conferred 
reversion of immunosuppressive microenvironment in tdLN into immune activation. B) 
Representative fluorescence images indicating retention of DiI labeled transfersomes in various 
tissues in vivo at 48, 96, 120, and 168 h after insertion of transfersomes complexed MNs. C) and 
D) Flow cytometry assay of the percentages of CD4
+
 T or CD8
+
 T cells among all lymph nodes 
or tumor tissue cells (n = 4). Data are expressed as mean ± SD. *p < 0.05, compared with MN. 
Reproduced with permission from ref.[109]; Copyright 2020, Springer Nature. 
 
4.1.3. Design of MNs for cancer immunotherapy by CTLA-4 blockade 
CTLA-4 is known as a protein receptor that acts as an immune checkpoint. CTLA-4 is expressed 
on T cells in lymph nodes, and its physiological interaction with APCs results in suppressing the 
activation of T-cells and the inflammatory response [82, 110]. Antibodies directed against 
CTLA-4 have been the first treatments in the class of immune checkpoint inhibitors to gain 
approval for the treatment of melanoma [111]. However, this target is systemically expressed, 
and the interference with this signal induces the emergence of immune-related side effects [112]. 
In order to improve the local delivery of anti- CTLA-4 and hinder systemic drug exposure, 
nanotopography-based MN array (MNA) can be applied. As an example, Kwon et al. designed a 
nanotopography-based MNA composed of a single-use, 66 mm
2
 arrays of 100 MNs of 110 μm 
diameter, 350 μm long, and with a 30 μm hole located off-center (named SOFUSA
TM
) to allow 
the delivery of anti- CTLA-4 into tdLN in an orthotopic mammary carcinoma murine model 
[113]. Repeated treatment with SOFUSA
TM
 inhibited tumor growth and metastasis development 
in bone, lymph nodes, and lungs better than the traditional systemic administration, an 
intraperitoneal administration (IP) of anti-CTLA-4 at 10 mg/kg. Moreover, the authors evaluated 
the transport of liquid from SOFUSA
TM
  to the brachial lymph nodes by infusing 100 μL/h of 
indocyanine green (ICG) into the epidermal spaces using near-infrared fluorescence imaging 













As mentioned above about cancer immunotherapy by PD-L1 blockade, a single treatment 
modality might be unable to efficiently treat malignant skin melanoma. To this end, Chen et al. 
designed a physiologically self-degradable MN-assisted platform to combine immunotherapy 
and photodynamic therapy (PDT) through controlled co-delivery of checkpoint inhibitor anti-
CTLA4 antibody (aCTLA4) and photosensitizer (PS) and create synergistic effects against 
tumors [114]. The hydrophobic (Zinc Phthalocyanine) and hydrophilic agents (aCTLA4) were 
synchronically encapsulated into the pH-sensitive dextran NPs using a double emulsion 
water/oil/water (w/o/w) evaporation method. The acetylation of the dextran pendant hydroxyl 
moiety resulted in the co-loading of hydrophobic photosensitizer/hydrophilic antibodies into the 
NPs. UV-Vis spectra of co-encapsulated NPs showed an absorption peak around 490 nm that 
was an indicator of the successful encapsulation of aCTLA4-FITC. Then, the pH-sensitive 
dextran NPs were embedded into the biocompatible HA MNs. In vivo experiments in 4T1 mouse 
models showed that three-times of MN insertion in combination with laser resulted in sustained 
tumor inhibition, while other treatment groups failed to create this outcome. The authors stated 
that the first destroying of partial tumor by PDT resulted in the initiation of the immune response 
that in turn, facilitated aCTLA4-mediated immunotherapy in the next step. Additionally, 
preliminary systemic assessments demonstrated that the engineered MNs had favorable safety 




4.2. Design of MNs for the delivery of therapeutic cancer vaccines 













Unique properties of DNA vaccine technology, including stability, simplicity, and safety, make 
them attractive immunotherapeutic approaches to treat cancers [115]. In this technology, the 
resulting immune responses can be manipulated by designing genes in DNA vaccines to encode 
immunomodulatory molecules and various antigens [116]. Currently, several research groups 
loaded DNA vaccines in the MNs to treat various cancers [52, 117, 118].  
The poor targeting of APCs and the lack of appropriate adjuvants have been major limitations in 
the transdermal delivery of a DNA vaccine for cancer immunotherapy [119]. To circumvent 
these shortcomings, Xu et al. fabricated a MN composed of a DNA vaccine in a polymeric 
nanocomplex, encapsulating a low concentration of paclitaxel (PTX) [120]. This MN patch was 
developed as a DC-targeted transdermal strategy for cancer immunotherapy, exploiting low-dose 
PTX as an adjuvant. They firstly synthesized a DNA plasmid that encodes GM-CSF, a DC 
chemoattractant cytokine, and a fusion protein of tyrosinase-related protein-2 (Trp-2), as a 
melanoma tumor antigen. In order to facilitate targeting to the mannose receptors present on 
DCs, the resulting plasmid was incorporated into a mannosylated N,N,N-trimethyl chitosan 
(mTMC) solution. At the same time, PTX at a low concentration was encapsulated in 
sulfobutylether-β-cyclodextrin (SBE), as a solubility enhancer and polyanionic linker. In the next 
step, ionic interactions between the cationic complex of mTMC/DNA and the negatively charged 
inclusion complex of PTX/SBE resulted in the creation of the PTX/SBE-mTMC/DNA 
nanocomplex. This DC-targeted nanocomplex can efficiently improve the maturation of DCs, 
with an increase in the secretion of IL-12p70. Furthermore, DCs pulsed with the nanocomplex 




 T cells, as well as decrease the percentage of 
immunosuppressive FoxP3+ Tregs. The co-delivery of DNA vaccine, mannosylated chitosan, 













growth compared to only DNA vaccine or only mannosylated chitosan/PTX in in vivo 
experiments in mice. It has been reported that incorporation of pH-responsive copolymers into 
the structure of MNs can accelerate the release of DNA vaccine in tumor acidic pH 
microenvironment [121]. Recently, Duong et al. designed and fabricated a smart DNA vaccine 
delivery system using polycarbonate MNs coated by layer-by-layer (LbL) deposition. The two 
layers are composed of positively charged ultra-pH-responsive oligo sulfamethazine conjugated 
poly(β-amino ester urethane) (OSM-(PEG-PAEU)) and a negatively charged immunostimulatory 
adjuvant, polyriboinosinic:polyribocytidylic (poly(I:C)), at low pH, to facilitate the controlled 
release of DNA vaccines and adjuvants in the immune cell-rich epidermis/dermis layer of the 
skin [122]. It was shown that the pH-sensitivity of OSM-(PEG-PAEU) led to the protonation of 
the copolymer to positively charge at pH 4.0, capable of forming a complex with poly(I:C) and 
hampering the release of the OVA- expressing plasmid (pOVA) and poly(I:C) from the LbL 
coated MNs. In addition, the presence of ionized sulfonamide moieties in the OSM oligomers 
resulted in the deprotonation of OSM-(PEG-PAEU) copolymer at the physiological pH (pH 7.4), 
resulting into a negative charge and facilitating the release of pOVA and poly(I:C) via 
electrostatic repulsion. The combined delivery of the DNA vaccine and adjuvant by the LbL 
coated MNs resulted in the induction of type I interferons followed by the production of antigen-
specific antibodies by B cells and the priming of CD8
+
 T-cell. The antigen-specific CD8
+
 T-cells 
induced the production of interferon-gamma (IFN-γ) and enhanced cancer cell death. In vivo 
experiments showed that the LbL-coated MNs resulted in higher OVA protein expression 
compared to the group where the plasmid was subcutaneously injected, which may be attributed 
to the penetration of MNs, of ca. 600 μm height, to the dermis, and the presentation of 













formulation, implantation of the LbL-coated MNs loaded with pOVA and poly(I:C) in mice 
caused a threefold increase in IFN-γ positive tumor-infiltrating CD8
+
 T cells and threefold higher 
amounts of anti-OVA IgG serum antibody, indicating suitable stimulation of the humoral and 
cellular immune response.  In another study by the same group, an array of dissolving MN was 
prepared using a bioresorbable polypeptide matrix  (mPEG5K–PN2LG30),  with nanosized 
polyplexes composed of pOVA and poly (I:C), which were loaded into high-transfection cationic 
amphiphilic conjugates (DA3) and added to the polypeptide matrix (Figure 8A) [123]. The 
positive charge of polyplex improved its uptake by DC 2.4 cells and RAW 264.7 macrophage 
cells (Figure 8B and 8C) and created a repulsive force on the other cationic copolymers, which 
resulted in burst release of ca. 85% of poly(I:C) and ca. 97% of pOVA within 5 min of 
application of the MN. This indicated the suitability of the MNs for future clinical use owing to 
the short treatment time with improvement of patient convenience. Additionally, the MN 
dissolved in the interstitial fluids of skin, mainly due to the presence of the polyethylene glycol 
(PEG) component in its structure. In vivo and in vitro experiments demonstrated the higher 
expression of OVA in the dissolving MN group compared to control and subcutaneous injection 
groups (Figure 8D), suggesting that the nanopolyplex can reach APCs, such as DCs and 
macrophage cells in the epidermis/dermis layers, and can be effectively captured by them. The 
administration of pOVA through dissolving MNs resulted in higher antibody titer (Figure 8E and 
8F) while reducing the number of OVA-expressing metastatic foci through antibody-dependent 















Figure 8. Dissolving MN polypeptide cocktails comprising of cationic nanopolyplex containing 
ovalbumin-expressing pOVA and poly(I:C) for cancer immunotherapy. A) A schematic 
representation of the proposed anticancer mechanism of dissolving MNs containing mPEG5K–
PN2LG30 and the nanopolyplex (DA3 and (pOVA + poly (I:C)). The dissolving MNs interact 
with mature APCs followed by stimulation of antiOVA antibody production for ADCC of cancer 
cells. Confocal microscopy images of in vitro cellular uptake of the nanopolyplex released from 
dMN arrays in B) DC 2.4 and C) RAW 264.7 cells, respectively. Scale bar = 20 mm. D) Double 
immunohistofluorescence staining showing the in vivo OVA protein expression in DCs. E) 
Serum levels of Anti-OVA antibody IgG1 after one week in different experimental groups (*p < 
0.05, **p < 0.01, ***p < 0.001, n = 3). Serum levels of Anti-OVA antibody IgG1 were markedly 
elevated in DA3/(pOVA + poly (I:C) compared to negative control and subcutaneous injection 
(SC) groups. F) Serum levels of Anti-OVA antibody IgG1 before and after challenge with OVA 
protein (*p < 0.05 and **p < 0.01, n = 5). Serum levels of Anti-OVA antibody IgG1 markedly 
increased in MNs compared to SC groups after challenge. Reproduced with permission from 
ref.[123]; Copyright 
 

















4.2.2. MNs for effective delivery of other cancer vaccines 
One of the primary objectives of cancer immunotherapy is the establishment of a broad tumor-
targeting T cell repertoire that is able to recognize and destroy heterogeneous tumor cell 
populations. One promising strategy is in situ vaccination that contributes to starting a selective 
and durable adaptive immune response using the diverse collection of tumor antigens within the 
tumor. Moreover, in situ vaccination plays an important role in reprogramming the TME toward 
an immunostimulatory state. The high interstitial fluid pressure of the TME can act as a barrier 
for immunotherapeutic agents to enter into the tumor. To address this limitation, Boone et al. 
developed an autonomous active MN for the direct transportation of cowpea mosaic virus NPs 
(CPMV) as potent immunoadjuvants towards the treatment of B16F10 melanoma in mice [124]. 
In this system, magnesium (Mg) microparticles were embedded into active MNs to facilitate the 
entrance of the NP payload into the tumor through their reaction with the interstitial fluid in the 
TME and creating a propulsive force. In vivo experiments demonstrated that active MNs strongly 
increased tumor regression, improved survival profiles of tumor-bearing mice, and represented 
enrichment in the CD8
+
 T cell population. As mentioned in the previous section, combination 
therapy of cancer using immune-stimulating antigens and other techniques can be considered as 
a valid approach to more effectively treat cancers than monotherapy. One of the promising 
strategies to improve the anti-tumor immune responses is the vaccination with whole tumor 
antigens derived from whole cell lysates. In addition to whole tumor antigens, the whole cell 
lysates possess melanin that can as a photosensitizer for heat generation and subsequent PTT of 
cancer [125]. As an example, Ye et al. reported the design and fabrication of a transdermal 













loaded with B16.F10 whole tumor lysate containing melanin and granulocyte-macrophage 
colony-stimulating factor (GM-CSF). In addition to the sustained release of lysate into the skin, 
melanin can act as a photosensitizer for heat generation through localized near-infrared light 
(NIR) irradiation, while the presence of GM-CSF enhances the recruitment and activation of 
immune cells. In vitro experiments demonstrated that 10 min of NIR irradiation provided an 




cells, increasing from 36.7 ± 2.3% to 48.9 ± 
3.1% after 10 min) and did not reduce their viability and functionality. In vivo experiments in a 
prophylactic set up in B16.F10 models indicated that the combined therapy of MNs loaded with 
tumor lysate and GM-CSF with NIR irradiation resulted in complete tumor rejection in 87% of 
the treated mice and long-term survival. Furthermore, the authors analyzed also the 
immunological mechanisms responsible for the vaccination efficacy by testing the MNs in 
animals genetically modified not to express lymphocytes (both T- and B- cells) to evaluate the 
contribution of the adaptive immunity, or treated with diphtheria toxin receptor to deplete DC to 
assess the contribution of the innate immunity and antigen processing and presentation. The 
results highlight the importance of both components in the instauration of an optimal immune 
memory against future tumor challenges. These MNs are also able to control tumor growth in a 
therapeutic setup after NIR irradiation. Furthermore, this immune response is systemic and able 
to affect distal, non-treated, or irradiated tumors. 
In the case of IM or subcutaneous vaccination, patients might experience stress, fear, pain, and 
undesirable specific immune responses. In this regard, using MNs can be a good choice to 
achieve maximum delivery while limiting side effects. To this end, Lee et al. used a MN 
containing the antigen OVA as an immune-stimulating antigen delivery system to activate anti-













exhibited a significantly reduced tumor size (78.75±30.1 mm
3
) and weight (0.82±0.5 gr) 
compared to a control patch, which had a tumor size and weight of 249.67±39.1 mm
3
 and 
2.33±0.9 g, respectively. This observation was mainly attributed to the increased population of 
OVA-specific CD8
+
 T cells and CD4
+
 T cells. These cells were responsible for the cytotoxic 
effect against the graft of OVA-expressing EG7 tumor cells.  
In another example, an amphiphilic triblock copolymer (Pluronic F27) was employed in 
constructing a dissolving MN-based cancer vaccine able to create nanomicelles (NMCs) in the 
intradermal fluid (Figure 9A) [128]. The amphiphilic property of the Pluronic F27 enabled the 
co-delivery of OVA, hydrophilic, and resiquimod (R848), hydrophobic, into in situ micelles 
formed after cutaneous application, contributing to the dissolution of R-848. In vitro experiments 
confirmed the immunostimulatory potential of R848 encapsulated within the NMCs. 
Furthermore, upon administration of the MN patch in vivo, the NMCs can efficiently migrate to 
lymph nodes and induce antigen-specific humoral and cellular immunity in EG7-OVA tumor-




 T cells and reduction in 
tumor size and weight were found in mice treated with OVA/R-848 MNs compared to the mock 














Figure 9. The amphiphilic triblock copolymer-based dissolving MNs containing OVA and R848 
with the ability for in situ generation of NMCs and inhibition of tumor growth upon their 
dissolution after cutaneous application in EG7-OVA tumor-bearing mice. A) Schematic 
illustration of dissolving MNs for co-delivery of hydrophobic immunomodulators and tumor 
antigens via in situ formation of nanomicelles. B) OVA-specific IgG levels after immunization 




 T cells in different experimental groups (**p 
< 0.01, n = 5). Co-delivery of R-848 and OVA by MNs resulted in a higher percentage of IFN-
γ+CD8+ T cells compared to the mock and the MNs containing antigen only.  D) Tumor size 
from the three experimental groups. The mock group only received PBS (**p < 0.01 compared 
to mock group, n = 5). E) Tumor weight in different experimental groups (*p < 0.05 and **p < 
0.01, n = 5). The MNs containing antigen only (OVA) contribute to a partial control over the 
tumor growth, as demonstrated by the reduction of the tumor weight when compared to the 
mock. However, the administration of the complete formulation, antigen, and adjuvant (R-848) 
in the same MNs results in a higher activation of the immune system and better control over the 
tumor growth. Reproduced with permission from ref.[128]; Copyright 2018, American Chemical 
Society.  
 
In conclusion, MN patches represent an excellent alternative to conventional cancer vaccine 












have proposed innovative formulations to allow a simple simultaneous delivery of antigens and 
adjuvants with opposite hydro/lipophilic characteristics or enabling efficient delivery of the 
payload to the draining lymph nodes. Finally, MNs can also play a role in improving the efficacy 
of immune checkpoint inhibitors, allowing for local delivery in the tumor area with a decrease in 
the immune side effect associated with systemic delivery.  
 
5. Autoimmune diseases 
Currently, MNs have been extensively investigated to precisely treat or manage autoimmune 
diseases, such as type 1 diabetes (T1D), alopecia areata, systemic lupus erythematosus, multiple 
sclerosis, and rheumatoid arthritis (RA) [129-133]. The direct administration of 
immunomodulatory peptides and immunosuppressive drugs to patients with the traditional 
techniques is no longer applicable owing to their intrinsic limitations such as poor oral 
bioavailability, gastrointestinal side-effects, enzymatic hydrolysis in the gastrointestinal tract, 
rapid plasma clearance, and poor patient compliance [134]. To address some of these limitations, 
Lin et al. developed dissolving MNA to deliver Thymopentin (TP5), a synthetic pentapeptide 
with a very short half-life in plasma (about 30 s) and immunomodulating properties for the 
treatment of autoimmune diseases, in immunosuppressed Sprague-Dawley rats [135]. A MN 
array containing TP5 was fabricated by a modified two-step molding technology using bovine 
serum albumin (BSA) as a mechanical strength regulator. The high-performance liquid 
chromatography (HPLC) chromatogram confirmed the maintenance of the integrity of TP5 after 
loading in the MN patch. The administration of TP5 through the MNs improved the levels of T-

















In 2020, Ahmad et al. fabricated thiolated chitosan (TCS)-based MN patch containing tacrolimus 
(TM), an immunosuppressant agent for the treatment of autoimmune disorders, by a mold casting 
method. The TCS-based MN patch was able to improve the drug bioavailability through 
circumvention of the hepatic first-pass metabolism and intestinal P-gp efflux and deliver the drug 
in a more sustained manner than oral administration [136]. Attenuated total reflectance-Fourier 
transform infrared (ATR-FTIR) analysis demonstrated that characteristic peaks of TM were 
retained in MN patches, suggesting the stability of TM during the preparation process of the 
patches. The author found the best tensile strength (0.05 mPa) at 2% concentration of TCS and a 
higher skin distribution for MN-TM (15.34 ± 2.4%) compared to ointment (9.45 ± 3.2%). 
Additionally, they further mentioned 84% penetration of TM with no breakage of the MNs and a 
sustained release (82.5%) from patches with no visible erythema or edema.  
 
5.1. Design of MNs for immunotherapy of type 1 diabetes  
The loss of T-cell-dependent immunological tolerance to β-cell autoantigens has been proposed 
as the most critical pathological event of T1D. A possible solution for the optimal treatment of 
this disease is to reverse this process [137]. Antigen-specific immunotherapy (ASI) is a 
promising therapeutic strategy to treat T1D through the induction of an immune regulatory 
response to hinder autoimmune-mediated β-cell destruction to maintain insulin production [138]. 
Peptide immunotherapy has been proposed as promising strategy to induce tolerance to 
pancreatic self-antigens. A key aspect to consider in MNs is to analyze their advantages 
compared to an ID injection. In a comparative study for the delivery of four different antigenic 
peptides, including WE 14, Insulin B9-23, Epstein–Barr virus peptide 280–288 and BDC2.5 













patches consisting of methyl butanol, polyvinyl alcohol, and acetic acid exhibited a more 
effective delivery and prolonged antigen presentation in the skin [139]. Comparable reductions 
in the auto-reactive cell proliferation were observed when the authors immunized the animals 
with two concentrations of WE14 (6 μg of the peptide in dry-coated MNs and 50 μg of the 
peptide in ID injection) (Figure 10A). The results can be mainly attributed to the higher retention 
time of the peptide-loaded into the MN patch, which in turn resulted in providing enough time 
for the APCs in the skin to tender antigenic peptides to the patrolling T cells and create tolerance 
at lower peptide concentration. In order to minimize immune stimulation and control the 
localized kinetics in immunotherapy of T1D, nanomaterials with anti-inflammatory properties 
can be used as appropriate multi-cargo delivery platforms to present tolerogenic auto-antigens to 
APCs and promote a regulatory response. In another example, Dul et al. used MicronJet600, a 
clinically approved MN delivery system, to treat T1D through intradermal delivery of a human 
leukocyte antigen-DR4 (HLA-DR4)-restricted peptide epitope of proinsulin (C19-A3) tethered to 
gold NPs (GNPs) (Figure 10B) [140]. Ex vivo experiments showed that GNPs quickly diffused 
throughout human skin. Additionally, in vitro experiments indicated that uptake of GNPs -
peptide complexes by DCs resulted in a reduction of their capacity to active naïve T cells. 
One of the major disadvantages of the above-mentioned studies for T1D immunotherapy is the 
loading of a single peptide autoantigen in the MNs, which in turn can limit their applications to 
sub-populations of patients with a specific human leukocyte antigen (HLA) molecule [141]. It 
has been reported that using coated MN systems loaded with complete protein containing 
multiple epitopes provide high therapeutic potential for ASI of T1D because of the ability of 
APC to synchronically generate tolerance to a range of epitopes and be therapeutically applicable 













Following this concept, Arikat et al. developed Proinsulin (PI)-coated MNs to transport PI 
protein into the superficial layers of the skin, targeting immature epidermal Langerhans cells 
(LCs) and steady-state DCs, which exhibit tolerogenic functions [142]. The presence of 
polysorbate 80 as a non-ionic surfactant in the coating formulation resulted in the uniform 
coating of protein onto the outer surface of MNs. The authors found that the delivery efficiency 
of PI was 77.5 ± 17.3% after 1 minute of MN application and increased to 86.1 ± 4.4% after 2.5 
minutes. Based on in vivo experiments in NOD female mice, significant proliferation of 
adoptively transferred G9 CD8
+
 T cells was seen in the draining (axillary) lymph nodes (AxLNs) 
in the MN treated group (29.1%) while traditional ID PI injection failed to create this effect 
(4.6%).  
It can be assumed that compared to conventional ID routes, delivery by coated MNs (dry coating 
of therapeutic antigen onto their outer surface) for treatment of T1D represents a valid method 
with numerous advantages, such as highly efficient antigen delivery to the dermis and epidermis, 
capacity for the co-delivery of multiple therapeutic agents, the prolonged retention time for 
therapeutic antigens in the skin, the possibility of sustained exposure of APCs to low 
concentrations of therapeutic antigens, less pain, no bleeding and distension of skin layer, with 
less skin damage and subsequent infection [143-146]. 
 
5.2. Design of MNs for Rheumatoid Arthritis immunotherapy  
RA is a long-term autoimmune or chronic inflammatory disorder that can cause progressive 
disability of synovial joints owing to inflammation of synovial membrane, cartilage, and bone 
damage [147]. Glucocorticoids are frequently used in the short term to relieve pain and 













Immunotherapy aims to reduce inflammation and protect the integrity of the joint, with 
manageable side effects [148]. Topical drug delivery is only able to deliver therapeutic 
molecules with proper oil-water partition coefficient, low molecular weight, and low melting 
point due to the characteristics of the stratum corneum [149].   
To address these challenges, Yao et al. developed a neurotoxin (NT)-loaded dissolving MNs 
through two-step centrifugation, with 15.4 ± 0.5 μg of the drug-loaded in the upper part of each 
needle [150]. The MN exhibited good mechanical properties and less toxicity on chondrocytes. 
The MN could penetrate the skin at a depth higher than 70 μm. Also, the cumulative penetration 
of NT in MNs reached 95.8% in 4 h, whereas a NT solution could hardly penetrate the skin. 
After administration to animals, NT-MNs were capable of suppressing the secretion of pro-
inflammatory cytokines such as the tumor necrosis factor α (TNF-α) and interleukin 1 β (IL-1β) 
as well as reduce the toe swelling of RA rats. 
Although nonsteroidal anti-inflammatory drugs (NSAID), such as meloxicam, are widely used to 
reduce inflammation and protect the integrity of the joint in RA patients, their long-term use 
results in poor patient compliance due to their serious side effects such as hypertension, diabetes, 
ulceration and gastrointestinal perforation [151]. 
In order to highlight the compliance of MN technology, Amodwala et al. developed fast-
dissolving MNs loaded with meloxicam as a patient-friendly tool to promote drug delivery to 
deeper layers of skin and circumvent the drug’s poor patient compliance owing to 
gastrointestinal disturbances after oral administration [152]. They reported a 2.58-enhanced 
penetration, improved transdermal flux of 1.60 μg/cm
2
/h, and 63.37% deposition of meloxicam 
in excised rat abdominal skin compared to the drug solution. Moreover, rats treated with the MN 













interesting example, Chen et al. went on to address the limitations of NSAID through the design 
and fabrication of tip-dissolving MNs. In their study, polymer solutions containing meloxicam 
were added into the PDMS mold, and high pressure was exerted to drive the air bubbles out of 
the cavities of the mold. In the next step, the residual solutions were removed to facilitate drying 
the tip solutions in the cavities of mold. Finally,  molten polycaprolactone (PCL) was poured into 
the mold, and high pressure was exerted again [153]. The author pointed out that tip-dissolving 
MNs exhibited burst release of the encapsulated meloxicam (91.72% within 30 min), excellent 
bioavailability (122.3%), favorable drug transportation to the skin (79.18%), high anti-
inflammatory and analgesic activities without any adverse effects such as skin irritation. In 
another study, Cao et al. engineered dissolvable HA crosslinked MNs as the transdermal 
alternative to deliver etanercept (EN), a TNF- α inhibitor for RA therapy since the subcutaneous 
(SC) injection of EN is associated with low compliance, infection risk, and other side effects 
[154]. The engineered MNs exhibited good mechanical strength and excellent biocompatibility 
and did not reduce the bioactivity of EN. In vivo experiments in adjuvant-induced arthritis mice 
showed that treatment with both EN by SC (eSC) and EN by MN (eMN) reduced the paw 
swelling ratio from 1.70 to 1.48 and 1.68 to 1.44 in 10 days, respectively, indicating anti-
inflammatory effects. Additionally, ELISA assay showed significantly reduced serum levels of 
the TNF-α and IL-6 level in both eSC and eMN mice compared to the mice that were treated 














Figure 10. Comparing ASI of T1D using dry coated MNs or ID administration. A) Measuring 
the auto-reactive cell proliferation (proliferated BDC2.5 T cells) in the pancreatic lymph node 
after WE14 administration by ID injection or MNs.  (**p<0.01). MNs with low peptide 
concentration (6 µg) exhibited similar efficiency to ID injection with high peptide concentration 
(50 µg) in reducing proliferated BDC2.5 T cells and inducing tolerance. Reproduced with 
permission from ref.[139] Copyright 2016, Elsevier B.V. MicronJet600 for ID delivery of 
proinsulin (C19-A3) tethered to GNPs towards T1D immunotherapy. B) Schematic 
representation of the delivery of AuNP-peptide complexes into the skin by MNs and their 
subsequent quick diffusion throughout the skin, capturing by APCs and suppressing activation of 
naïve T cells. Reproduced with permission from ref.[140] Copyright 2019, Elsevier B.V. C) the 
TNF-α and D) IL-6 serum levels in different experimental groups. * p < 0.05 vs. SA. NS 
represents no significance. Reproduced with permission from ref.[154]; Copyright 2019, MDPI. 
 
In another study, Qiu et al. designed and prepared dissolvable MNs loaded with artemether, a 
drug for RA treatment, to address the poor water-solubility of this drug [155]. The dissolving 
MNs were capable of delivering 72.67±2.69% of the initial dose of artemether into the skin. 













h after administration compared to IM injection. The authors found an analogous reduction in 
total anti-CII IgG levels in collagen-induced arthritis rats compared to MI injection. 
Some previous studies have shown that the combination therapy of RA possessed higher effects 
in reducing inflammation compared to monotherapy [156]. Yu et al. designed and fabricated a 
dissolving MN system containing immunosuppressant tacrolimus (TAC) and anti-inflammatory 
diclofenac (DIC) in different layers of MNs, named TD-MN (Figure 11A) [157]. The tip-layer of 
TD-MN was composed of a blend of dextran, HA, PVP K17 and DIC or RhB. The inter-layer 
was included a blend of dextran, HA, PVP K17, and TAC. In vitro and in vivo experiments for 
skin permeation showed that the inter-layer was able to retain TAC within the skin of ∼100 μm, 
whereas the tip-layer transported DIC up to ∼300 μm into the articular cavity. The fluorescence 
images of the rat knee joints punctured by the layered MNs loaded with RhB demonstrated that 
the RhB fluorescence quickly entered in the articular cavity. This claim was confirmed by 
removing treated skin after 30 min. A gradual increase of the fluorescence intensity of RhB was 
seen over 6 h, and remained high for 24 h (Figure 11B). compared to the layered MNs, the intra-
articular injection of RhB solution showed a peak at 4 h post-injection, and a very low amount of 
RhB was maintained from 6 to 12 h post-injection (Figure 11C). In vivo experiments indicated 
that the TD-MN alleviated carrageenan/kaolin-induced arthritis compared to DIC injection by 
reducing cartilage destruction, muscle atrophy, and joint swelling. Significantly reduced levels of 
the serum TNF-α and IL-17A in arthritic rats treated with the TD-MN were found, while 
unlayered MNs loading a mixture of TAC and DIC (MIX-MN) failed to create protective effects 
(Figure 11D and 11E). These findings suggest that the synergistic effects highly rely on the 
effective integration of multiple therapeutic agents in different layers of a single platform rather 














Figure 11. The TD-MN containing tacrolimus (TAC) and diclofenac sodium (DIC) in different 
layers for combined therapy of RA and psoriatic skin. A) Schematic representation of layed MNs 
for combined therapy of RA and psoriatic skin though modulation of inflammation. The tip-layer 
of TD-MN was composed from a blend of dextran, HA, PVP K17 and DIC or RhB.  The inter-
layer was included a blend of dextran, HA, PVP K17 and TAC. B) In vivo fluorescence images 
of RhB transportation of layered MNs into the articular cavity of rats at 0.5, 1, 2, 4, 6, 9, 12, and 
24 h. C) In vivo fluorescence images of intra-articular injection of RhB solution at 0, 0.5, 1, 2, 4, 
and 6 h. Effects of various MN formulations on serum levels of D) TNF-α and E) IL-17A in 
arthritic rats. Data are expressed as mean ± SD (n=6 animals per group). ∗P<0.05 versus 
carrageenan/kaolin-induced arthritic model group; 
#
P<0.05 versus MIX-MN group; and ns, no 
significant difference versus the negative group. Definition of MIX-MN group: Loading a 
mixture of TAC and DIC into the unlayered MNs. Reproduced with permission from ref.[157]; 
Copyright 2020, Elsevier B.V. 
 
In another study, Zhao et al. used bee venom gel instead of NSAID to prevent the occurrence of 
gouty arthritis inflammation in rats. The authors used MNs containing bee venom gel and found 













inflammatory effects [158]. For example, another type of hydrogel MNs encapsulated triptolide-
loaded liposomes as novel systems to treat collagen-induced arthritis in rats [159]. In this study, 
the pharmacodynamics experiments demonstrated that the MNs attenuated the degree of joint 
swelling and serum levels of IL-1β and interleukin-6 (IL-6) through regulation of the balance 
between Th1 and Th2 pathways. In summary, the possibility to transdermally deliver therapeutic 
molecules using MNs for RA treatment represents a great advantage for their clinical translation 
since they can reduce the adverse effects of RA drugs. 
 
6. Defeat allergy by MN patches 
6.1. Design of MNs for immunotherapy of food allergies 
Food allergens like peanut, milk, gluten, and aeroallergens, such as pollen and dust, can 
stimulate immune cells and result in the secretion of pro-inflammatory cytokines, activation of 
IgE antibodies, mast cells, and eosinophils [160-162]. Allergy immunotherapy promotes 
immunological tolerance, with a long-term effect lasting past treatment termination [163]. In a 
study, Shakyaa et al. used peanut protein extract (PE)-coated MNs to provide desensitization of 
peanut sensitized mice [164]. They firstly fabricated MNA from 50-μm thick stainless steel (304 
grade) sheets through a wet etch process and then coated them by dipping in a coating solution 
containing PE, carboxymethyl cellulose (as a viscosity enhancer), and Lutrol F-68 NF (as a 
surfactant). The authors further revealed that PE-coated MN group had significant down-
regulation of systemic anaphylaxis mediators like mast cell protease-1 (MCPT-1) and histamine 
and up-regulation of Th1 cytokines like interleukin-2 (IL-2) and IFN-γ compared to the untreated 
group, indicating that PE-coated MNs contributed to immune regulation by targeting the Th1 













coated MNs reduced the infiltration of eosinophils compared to the untreated group. It is well 
documented that the allergen dose delivered into the skin is a decisive factor of successful 
allergy immunotherapy [165]. As a result of some limitations of coated MNs, such as the 
difficulty of precise coating and insufficient delivery of therapeutic allergen, some researchers 
have used dissolvable MNA to ensure effective PE transportation into the epidermis/dermis 
layers. For example, Yu et al. showed that a powder-laden, dissolvable MNA (PLD-MNA) 
encapsulating peanut allergen (PNA)/ 1,25-dihydroxyvitamin D3 (VD3)/CpG could be used to 
manage IgE-mediated allergies in peanut-sensitized mice [166]. The authors revealed that the 
MNA was able to deliver most of its content after 1 h into the epidermis of mouse skin, with no 
evident skin irritation or leakage into the circulation. The intravital confocal microscopy of MHC 
class II–EGFP mice showed that OVA-555–laden PLD-MNA was dissolved into the mouse ears 
within 15 min, and the APCs were highly accumulated around each powder dot (OVA), with a 
peak on days 1 and 2. The emerged yellow colors of green and red on days 1 and 2 confirmed the 
uptake of OVA by APCs. Decreasing powder quantity in the epidermis from day 1 to day 5 
resulted in the gradual reduction in the number of APCs (Figure 12). The researchers further 
stated that PLD-MNA encapsulating PNA/VD3/CpG reduced clinical allergy scores (from 3.5 to 
1), the number of treatments, and the required dose of PNA in each treatment compared to 














Figure 12. The ability of OVA-555–laden PLD-MNA for attracting and activating APCs and 
promoting antigen uptake by these cells. Two-photon confocal microscopy for tracking OVA-
555 in the epidermis from day 0 to day 8. White triangles in upper panels show accumulation of 
APCs around each powder dot on day 1. White arrows indicate the merged yellow color of green 
and red owing to the uptake of OVA (red) by APCs (green). Scale bars represent 500, 200, and 
50 mm in the upper, middle, and bottom panels, respectively. Reproduced with permission from 
ref.[166]; Copyright 2020, Elsevier B.V. 
 
6.2. MNs for immunotherapy of allergic respiratory diseases 
Airway allergies, including allergic asthma, allergic rhinitis, and allergic conjunctivitis, are 
common public health concerns due to their increasing prevalence worldwide [167]. The release 
of toxic protein granules or ROS by infiltrated eosinophils at the site of inflammation enhances 
the allergic immune response [168]. Moreover, mast cells are a major effector cell type in IgE-
mediated hypersensitivity that induces airway allergies through releasing various inflammatory 
mediators, such as histamine [169]. A promising strategy for the treatment of airway allergies is 
allergen-specific immunotherapy (AIT). The principle of AIT  is based on repeated 
administration of an allergen with increasing doses until the achievement of tolerance [170]. AIT 













subcutaneous allergen-specific immunotherapy (SCIT).  SLIT is safe, but it needs high allergen 
doses and is not a satisfactory method for administration in kids and infants [171]. Although SCIT 
uses lower doses compared to SLIT, it is painful and inconvenient with other systematic side 
effects [172]. To overcome the limitations of SCIT, coated MNs can be applied to improve the 
efficiency of immunotherapy of allergic airway diseases. For example, Shakya et al. developed a 
coated MN with Ova and CpG (MNs-Ova+CpG) to evaluate its efficiency for allergen 
desensitization in a mouse model of Ova-induced airway allergy compared to SCIT [173]. The 
authors stated that treated mice were challenged with Ova through the nasal route to examine 
efficacy against allergen challenge. Treated mice with coated MNs demonstrated significantly 
increased levels of Ova specific serum IgG antibodies in comparison with SCIT-Ova+alum 
treated group. Likewise, up-regulation of anti-inflammatory cytokine IL-10, downregulation of 
pro-inflammatory cytokines, including IL-5 and IL-13, and activation of Ova specific immune 
response in bronchoalveolar fluid showed that (MNs-Ova+CpG have the ability to suppress the 
airway inflammation in allergic mice. Additionally, H&E stains for eosinophils and May-
Grünwald Giemsa (MGG) stains for mast cells showed that treatment with MNs-Ova+CpG 
markedly reduced infiltration of these cells in lung tissues compared to the untreated and the 













Figure 13. The effects of coated MN with Ova and CpG on the infiltration of eosinophils and 
mast cells in lung tissues. A) H&E stained lung tissue sections for evaluation of eosinophil 
infiltration. B) Eosinophil count. C) May-Grünwald Giemsa stained tissue sections for evaluation 
of mast cell infiltration. D) Mast cell count. Arrows show cells or mucus deposition (n = 3 
animals per group). Data are expressed as mean ± SEM. ** p ≤ 0.01, and ns: not significant. 
Reproduced with permission from ref.[173]; Copyright 2020, American Chemical Society. 
 
In another interesting example, the same research group loaded Der p 1, a house dust mite 
allergen, onto an MN patch composed of 57 total MNs to hamper the onset and progression of 
Der p 1–induced airway allergy [174]. Their results by calibrated fluorescence spectroscopy 
demonstrated that 73.3% ± 7.4% of coated Der p 1 was transported into the skin. The authors 













the untreated and subcutaneous immunotherapy groups. The addition of CpG as an adjuvant to 
Der p 1 coated MN resulted in a more significant anti–Der p 1 IgG2a response and higher IL-10 
and transforming growth factor-beta (TGF-β) secretion than both the Der p 1 coated MN and 
subcutaneous immunotherapy.    
In another example, Shakya et al. coated MNs, using an in-house micro-precision dip-coating 
device, in a solution containing OVA, Lutrol F-68 NF, and carboxymethylcellulose (1%, w/v) to 
create a preventive vaccine against airway allergy [175]. The authors stated that the coated MNs 
are beneficial for treating airway allergy in infants as the sublingual route is not suitable for 
them, and injections are painful. A strong OVA-specific systemic immune response was induced 
following the insertion of MN coated with OVA and CpG oligonucleotide as adjuvant into the 
mice’s skin. The MNs modulated a variety of cytokines, including anti-inflammatory cytokines 
(IL-10) and Th2 cytokines (IL-13, IL-4, and IL-5) in the bronchoalveolar fluid, as well as Th1 
cytokines (IFN-γ and IL-2) in re-stimulated splenocyte cultures, indicating improvement of 
clinical symptoms of allergy.  
Owing to limitations of coated MNs, Park et al. developed a biodegradable MN patch (MNP) 
comprising of hyaluronate and Dermatophagoides farinae (D. farinae) extract (DfE) using a 
droplet-born air blowing method for transdermal immunotherapy (TDIT) to ameliorate airway 
hyperresponsiveness (AHR) and inflammation in a house dust mite (HDM) asthma model 
(Figure 14A and 14B) [176]. The delivery test showed that 77% and 85.4% of the allergen were 
absorbed after 1 and 8 h of MNP insertion, respectively. In vivo experiments indicated that 
treatment with 10 μg TDIT improved HDM-induced AHR most significantly in comparison with 
low-dose (10 μg) and high-dose (100 μg) SCIT. TDIT had the strongest effect in reducing the 













and epithelium-derived cytokines (IL-33 and TSLP) as indicators of allergic inflammation 
(Figure 14C). Likewise, only treatment with 10 μg TDIT markedly increased Treg-associated 
cytokines (IL-10 and TGF-β), which are known to be expressed following AIT (Figure 14D). 
Their results showed that treatment with 10 μg TDIT resulted in the largest decrease in D. farina-
specific IgE and IgG2a. Histopathological experiments demonstrated that treatment with 10 μg 
TDIT reduced goblet cell hyperplasia, subepithelial fibrosis, and HDM-induced inflammation. 
 
Figure 14. The effects of a biodegradable MNP loaded with D. farinae extract in reducing 
airway hyperresponsiveness (AHR) and inflammation. A) Schematic illustration of MNP loaded 
with DfE on the skin. MNP loaded with DfE were dissolved into the skin after insertion. B) MNP 
insertion on BALB/c female mice. Flow cytometry analysis of C) T helper 2 (Th2) cells and D) 
Regulatory T cells in Sham (control), Asthma (without treatment), Low SCIT (10 μg), and High 
SCIT (100 μg), and TDIT (MNP loaded with DfE) groups. Data are expressed as the mean ± SD. 
#
P < 0.05 compared to asthma; 
##
P < 0.001 compared to asthma; *P < 0.05 and **P < 0.001 
between AIT modality (SCIT or TDIT). Reproduced with permission from.[176]; Copyright 














6.3. MNs for allergen-specific immunotherapy 
To compare the efficiency of MNs for cutaneous allergen-specific immunotherapy (ASIT) with 
other conventional routes like the IP, IM, and subcutaneous allergen immunotherapy, Shakya et 
al. fabricated MNs coated with OVA by a micro-precision dip coater and a coating solution 
containing OVA, carboxymethyl cellulose and Lutrol F-68 NF [177]. They demonstrated that 
most of the coating was transported into the skin following the insertion of the fluorescein-OVA 
coated MN patch in a mouse model. The coated MN-treated animals demonstrated an increased 
anti-OVA IgG response compared to IP and subcutaneous allergen immunotherapy and similar 
anti-OVA IgG response to IM administration at 28 days after insertion. Generally, they observed 
lower secretion of pro-inflammatory IL-1β, interleukin-13 (IL-13), interleukin-15 (IL-5), and IFN-
γ after the insertion of OVA coated MN patches compared to the other routes of administration, 
as well as higher activation of the Th1 pathway, indicating their potential use for painless ASI. 
The authors stated that a shift from Th2 to Th1 response is thought to be beneficial for ASI. 
In 2019, the same researchers coated two stimulators of interferon genes (STING) agonists, 
namely, cyclic diadenylate monophosphate (c-di-AMP) and cyclic diguanylate monophosphate 
(c-di-GMP), along with OVA as a model allergen on MN patches characterized by 57 individual 
micron-sized needles and transported them into mouse skin [178]. Calibrated fluorescence 
spectroscopy confirmed delivery of 78.8% (±4.2) of coated OVA into the skin, while 4.2% 
(±1.1) was seen on the skin and 17.0% (±4.0) OVA remained on the surface of MN patches. The 
authors showed a higher OVA-specific IgG2a antibody in serum as a surrogate marker for Th1 
type immune response and higher levels of Th1 cytokines (IFN-γ and IL-2) in re-stimulation of 














In a clinical trial conducted in Germany, Spina et al. compared MNs and adhesive-tape stripping 
in skin preparation for epicutaneous allergen immunotherapy [179]. They observed that MNs 
increased stratum corneum penetration in comparison to tape stripping and induced dendritic 
cell-mediated T cell responses. 
Benefitting from their tailorability to the location of different subtypes of dendritic cells, such as 
LCs, MN patches can be designed to target LCs for allergy immunotherapy with minimal side 
effects. The presence of LCs in the epidermal layer makes them the first line of APCs that meet 
skin-invading antigens. This opens up a new avenue for immunotherapy of diseases without 
causing noticeable adverse effects [180]. For example, Burg et al. designed microprojection 
arrays (MPA) in polycarbonate material through a hot embossing procedure and coated OVA 
onto the surface of the MPAs [181]. In this study, they found that slit-MPAs (110 μm ± 3 μm tall 
projections at 7k p/cm
2
) with higher tip surface areas than conical-MPAs (207 μm ± 5 μm tall 




)) were more suitable for only epidermal 
delivery using low application energies. They further stated that the mouse epidermis (eMPA) 
delivery with larger projection tip surface areas had a lower inflammatory response and 
epidermal cell death, lesser erythema after 24 h, and epidermal swelling after 72 h than dermal-
targeted MPAs (dMPA). Flow cytometry analysis showed that only the eMPA increased the 
migration of LCs with a low expression of major histocompatibility complex (MHC) II, without 
migration of dDCs.  
Overall, the delivery of allergens by MNs to both the epidermis and the dermis can be further 
explored as a convenient and effective new means of allergen immunotherapy, which would 















7. MN-based vaccines 
The need for improvement of percutaneous vaccination arises from several major limitations of 
this technique, including needle phobias, the need for high doses and reconstitution of 
lyophilized vaccines, and the production of a huge amount of biohazardous waste, including 
sharp materials, such as needles that require special disposal protocol [182]. 
Currently, vaccine-loaded MNs have attracted tremendous attention from the scientific 
community as safe and dose-sparing tools to control vaccine release kinetics or improve immune 
response through manipulation of the composites of MNs [183-185]. For example, DeMuth et al. 
developed layer-by-layer assembled polyelectrolyte multilayers (Poly-1/ICMV) deposited onto 
poly(lactic-co-glycolic acid) (PLGA) MNs, which provided a possibility to control the film 
thickness and dosage of immunomodulators for adjustable releasing and stabilizing goals (Figure 
15A) [186]. The authros firstly synthesized nanocapsules containing interbilayer covalent cross-
links among maleimide head moieties of adjacent phospholipid lamellae present in the walls of 
multilamellar vesicles and then deposited them onto the surface of PLGA MNs. By co-
encapsulating OVA as an adjuvant and a fluorescent tracer in the structure of nanocapsules 
loaded into MNs, they found that OVA was taken up by the APCs into the epidermis, which, in 
turn, gave rise to higher serum levels of anti-OVA IgG titers and improved humoral immune 
response in a mice model (Figure 15B).  
In another study, Boopathy et al. developed solid pyramidal MNs composed of silk fibroin (SF) 
protein tips encapsulating a stabilized HIV envelope immunogen and adjuvant to maintain drug 
concentrations in the skin by tailoring the speed of release [187]. It was shown that Env trimer 
was released over 2 weeks after immunization in the mice skin, resulting in increased germinal 













serum IgG titers (∼1,300-fold). Balmert et al. developed dissolving MNAs containing OVA plus 
Poly(I:C) via the combination of 3D laser lithography with nanoscale resolution and 
micromolding to compare its effects on induction of antigen-specific cellular and humoral 
immune responses with traditional IM [60]. The authors argued that this multi-component 
vaccine delivered 80.2% ± 12.5% OVA and 79.6 ± 5.0% Poly(I:C) within 10 min to murine skin 
(Figure 15C-15G). Likewise, epifluorescence microscopy showed penetration of MNs through 
the epidermis into the dermis for human skin, indicating MNs had suitable mechanical strength 
to penetrate into the human skin. The authors further stated that serum levels of anti-OVA IgG 
titers were markedly higher in immunized mice with multicomponent vaccine MNs compared to 
immunized mice with traditional IM injection. 
 
Figure 15. Transcutaneous vaccine delivery using releasable layer-by-layer assembly of 













multilayers onto PLGA MN surfaces, transportation into the skin after insertion, and boosting 
immune function. B) Serum levels of anti-OVA IgG titers at different days after immunization 
(
#
p < 0.05 and 
##
p < 0.01, and ***p < 0.001). Reproduced with permission from ref.[186]; 
Copyright 
 
2012, American Chemical Society. C) Amount of OVA and poly (I:C) transported 
into the skin at different time points after MN insertion (***p < 0.001). No significant 
differences for delivery of OVA were seen at different times after insertion (5, 10, and 20 min), 
whereas the highest transportation of poly (I:C) was observed 20 min after insertion. D) Optical 
stereomicroscopy and fluorescence images of MNs containing both Alexa555-OVA (red) and 
Alexa488-Poly (I:C) (green). Scale bar: 500 μm. E) Optical stereomicroscopy photo of 
OVA/Poly (I:C) loaded MNs after insertion in murine skin. Scale bar: 250 μm. Effective 
transportation of (F) Alexa488-Poly (I:C) and (G) Alexa555-OVA into the mouse skin after MN 
insertion. Reproduced with permission from ref.[60]; Copyright 2019, Elsevier B.V. 
 
7.1. Design of MNs for transdermal delivery of viral vaccines  
The utility of vaccines can be improved by the use of coated and dissolving MNs since they are 
capable of carrying vaccines in a dried form [188]. The MNs can then release the components of 
the vaccine after dissolution in the epidermis/dermis, resulting in more thermostability and 
reducing the necessity for vaccine reconstitution as one of the steps of traditional percutaneous 
vaccine administration [189, 190]. The improved thermostability by coated and dissolving MNs 
provides the possibility to decrease or eliminate high costs relevant to the ―cold chain‖ for 
storage or transportation of vaccines [191, 192]. Additionally, MNA vaccines are advantageous 
to create immunization against infectious diseases (SARS and COVID-19) in that they possess a 
high potential for self-administration without the need for any specialized equipment or an 
applicator [193, 194]. Although it has been reported that hollow MNs can be applied to facilitate 
penetration of NP loaded with therapeutic antigens into the skin and induce higher antibody 
response and a higher amount of interferon-γ compared to IM injection, needle clogging during 
piercing of skin and resistance to flow can limit their application for vaccination [195].  
In the recent decade, a number of groups have used coated MNs for viral vaccinations since they 













vaccine stability [196]. For example, Shin et al. coated 2 and 10μg of GMP with the influenza 
vaccine onto the stainless steel MNs using the dip-coating process before delivering them into 
the skin of a mice model to evaluate the reduction in influenza susceptibility [197]. In this study, 
mice immunized with the vaccine antigen and 2μg of GMP demonstrated the highest level of IgG 
at the second and fourth week after insertion (7-fold and 2.8-fold higher than the vaccine alone) 
while mice immunized with the vaccine antigen and 10μg of GMP did not induce a significant 
IgG response. Furthermore, mice immunized with 2μg GMP and the virus exhibited stronger 
protective immunity, while mice immunized with 10μg GMP, and the virus demonstrated the 
lowest lung viral titer and rapid recovery rate. Thereby, the simultaneous delivery of the 
influenza vaccine and GMP by MNs improved both cellular and humoral immunity. In another 
example, Nguyen et al. designed and fabricated 800-µm-long polylactic acid MNs coated with L-
HBsAg s (a third-generation hepatitis vaccine) to investigate its efficiency compared to IM 
immunization [198]. It was shown that the coated MNs more effectively elevated IgG1 and 
IgG2a titers and increased thermal and freeze-thaw stability compared to IM immunization.  
Despite the potential benefits, several drawbacks of the coated MNs, such as poor coating 
efficiency and immunogenicity, might limit their future clinical use for viral and bacterial 
vaccinations [43]. The small surface area of the MNs results in delivering only small amounts of 
therapeutic molecules and antigens into the skin. To address this limitation, Maaden et al. coated 
pH-sensitive MNs with inactivated polio vaccine (IPV) particles and N-trimethyl chitosan 
chloride (TMC) through electrostatic interactions to achieve a sufficiently high antigen dose 
[199]. In their study, the MN surface was firstly decorated with pH-sensitive (pyridine) moieties 
and then coated with negatively charged IPV and a positively charged TMC. The authors coated 













analysis, the authors found 45 D antigen units IPV and 700 ng TMC per MN. The ex vivo 
experiments demonstrated the release of both IPV and TMC into the human skin, and in vivo 
experiments confirmed the induction of IPV specific antibody responses. Another possible 
solution to overcome the limitation of coated MNs for vaccination is to use dissolvable MNs 
[200].  
In another example, Erdos et al. developed dissolvable MNAs, consisting of trehalose and 
carboxymethyl cellulose, incorporating adenovirus vaccines (Ad5.OVA) with or without 
Poly(I:C) using a spin-casting technique to enhance the immunogenicity of skin-targeted 
adenovector vaccines [201]. The authors confirmed the dissolution of the MNAs upon skin 
insertion using optical stereomicroscopy. The multicomponent MNA vaccine platforms 
determined an increased OVA-specific lytic immunity compared to MNA containing 
adenovectors alone. In 2019, Chen et al. demonstrated that when inactivated influenza virus or 
OVA antigen is loaded into dissolving chitosan MNs, the delivery of inactivated influenza virus 
occurred in a sustained manner (up to 28 days), and induction of influenza-virus-specific IgG 
responses were higher than IM injection in mice (Figure 16A-C) [82]. 
 
7.2. Design of MNs for transdermal delivery of bacterial vaccines 
In 2017, Pastor et al. developed outer membrane vesicle-loaded dissolving MNs to generate 
intradermal immunization against enteropathogens like the bacterium Shigella through induction 
of specific systemic IgG and mucosal IgA [202]. In 2019, Zhu et al. developed pertussis toxin 
(PT) vaccine MNs to transdermally target immune cells against Pertussis (whooping cough) 
caused by the bacterium Bordetella pertussis [203]. PT vaccine MNs released antigen in a more 













level of PT-specific IgG via several pathways, mainly Th1 and Th17 pathways when compared 
to subcutaneous injection. In another study, Chen et al. designed and fabricated a MN 
incorporating F1 antigen-loaded liposomes (F1-liposomes) to deliver the F1 protein of Yersinia 
pestis and generate immunity against plague in a mice model [204]. Mice immunized with F1-
liposome demonstrated the highest levels of the anti-F1 IgG antibody titers after 45 days 
compared to mice immunized with PBS buffer or F1-Alugel.  
 
Figure 16. Immunity against influenza virus infection using patch-free chitosan MNs. A) 
Schematic illustration of the implantable chitosan (CS)-MNs with the ability to boost immune 
function via effective intradermal influenza vaccination through a sustained release profile. B) 
3D reconstruction of confocal images of rat skin showing the degradation of CS-MNs and 
release of inactivated influenza virus in a sustained manner. FITC-Chitosan MN and Alexa 594-
OVA signals were seen until 28 days after insertion of the MNs in the rat skin. C) Influenza-
virus-specific IgG responses after IM injection of influenza vaccine or treatment using MN 
vaccine (***P < 0.001, n=5). Significant differences were observed between IM saline, IM 
vaccine, and MN vaccine. Reproduced with permission from ref.[82], Copyright
 
2019, Acta 













of PT vaccine MNs compared to subcutaneous injection. No signals were seen for subcutaneous 
injection after 6h, while signals for MN insertion were observed until 12 h. Reproduced with 
permission from ref.[203]; Copyright
 
2019, American Chemical Society. 
 
8. MN-mediated treatment of inflammatory diseases 
MNs can reduce the required dose and adverse effects of anti-inflammatory drugs and contribute 
to the maintenance of the physical stability of their nanocarriers [205]. Currently, dissolving 
MNs have garnered much attention from the scientific community for immunotherapy of 
inflammatory diseases.  
8.1. MN design for psoriasis treatment 
Psoriasis is a chronic inflammatory disorder that is mainly characterized by vasodilation and 
immunological imbalance. The activation of NF-κB by some factors results in the initiation of 
inflammation in psoriasis [206]. The presence of T cells and DCs in the psoriatic lesions enhance 
the secretion of pro-inflammatory cytokines such as TNFα, IL-1β, IFNγ, IL-17, IL-22, and IL-23 
[207]. Currently, evidence has shown that MNs can effectively manage psoriasis [208]. 
An advantage of using the dissolving MNs for immunotherapy of inflammatory diseases 
compared with other types of MNs and traditional needles is the dissolution of the needles within 
the skin and hence no requirement for proper needle disposal or the fear of needle reuse [209]. 
Du et al. pioneered a project using dissolving MNP composed of HA loaded with Methotrexate 
(MTX) using a two-step micromolding process. The aim of the study was to enhance the efficacy 
of psoriasis treatment by targeting inflammatory responses [210]. The release of MTX reached 
52% within 10 min, 76%, and 87% at 30 and 60 min, mainly due to the water solubility of HA. 
In vivo experiments demonstrated a complete dissolution of MNP- MTX within 10 min resulted 
in a reduction in ear thickness, suppression of the IL23/IL17 axis, and imiquimod (IMQ) -













loaded MNs (13.8 μg) and oral administration at a double dose (27.6 μg) of MTX exhibited 
much milder psoriasiform dermatitis whereas oral administration at a same dose with MNs (13.8 
μg) failed to exert such protective effects (Figure 17A).  
In another study, Korkmaz et al. developed carboxymethyl cellulose-based dissolving MNs 
containing anti-TNF–α for localized ID delivery to reduce the immunosuppression associated 
with systemic administration of antibody and related adverse events [211]. The antibody cargo 
was incorporated in the needle tips using a micromilling/spin-casting fabrication method. The 
MNs nearly completely dissolved into the human skin explants and reduced the critical 
biomarkers of psoriasiform inflammation (epidermal thickness and IL-1β expression) in a 
psoriatic mouse model. The following year, the same group conjugated high molecular weight 
HA to the anti-TNF-α antibody in the same dissolving MNs to hinder the fast diffusion of 
antibodies from the target site to other body regions [212]. The high efficiency of this delivery 
method was assessed in human skin explants without antibody diffusion from the delivery site. 
8.2. MN for acne treatment 
One of the main causes of acne is inflammatory responses that occur in the sebaceous glands of 
hair follicles [213]. The proliferation of microorganisms in hair follicles in large quantities, 
especially Propionibacterium acnes (P. acnes), results in free fatty acid production, excessive 
production of reactive oxygen species (ROS), chemotaxis of inflammatory mediators, 
inflammatory cells, and finally the formation of acne lesions [214]. Therefore, simultaneous 
inhibiting bacterial growth and suppressing inflammatory responses are essential to achieve a 
successful acne treatment. 
Excessive production of ROS under pathological conditions (more than 500 μM) in 













release therapeutic molecules in a sustained manner based on ROS-induced degradation into the 
acne lesion site [215]. Based on this concept, Zhang et al. prepared ROS-responsive MNs 
containing poly(vinyl alcohol) PVA/ clindamycin (CDM) networks that were loaded into a 
substrate composed of HA and diatomaceous earth (DE) to improve interactions for the 
treatment of acne vulgaris, a common inflammatory skin disease caused by colonization of P. 
acnes (Figure 17B) [216]. The use of ROS-responsive MNs highly reduced the number of 
infiltrated inflammatory cells into the dermis in a P. acnes-induced mouse model while a CDM 















Figure 17. HA-based dissolving MNP loaded with methotrexate for psoriasis treatment. A) 
Comparison between therapeutic effects of MTX-loaded MNs (13.8 μg), oral administration of 
the same dose (13.8 μg), and a double dose (27.6 μg) of MTX on IMQ-induced psoriasis-like 
skin inflammation at day 7. (a) Representative images of left ear lesions, (b) H&E staining. 
Reproduced with permission from ref.[210], Copyright 2019, American Chemical Society. ROS-













proposed mechanism of ROS-responsive MNs containing CDM for the treatment of 
inflammatory acne vulgaris. The excessive production of ROS under pathological conditions 
(more than 500 μM) in inflammatory tissues results in the sustained release of drug molecules. 
C) Quantitative analysis of infiltrated inflammatory cells in different groups. Control group: 
negative control without treatment, CDM cream: treatment with 1 wt-% CDM cream, RR-MN 
group: ROS-responsive PVA/CDM MN patches, CDM MN group: CDM loading HA MN 
patches, NR-MN group: Nonresponsive PVA/CDM MN patches and blank MN group: blank 
MN patches without CDM (CDM dose: 0.4 mg per mouse). There were no significant 
differences between RR-MN and normal groups. D) Representative images indicating the 
significant reduction in the swelling volume of the RR-MN treated back skin of P. acnes-induced 
mice on day 6 after MN insertion. Scale bar: 5 mm. Reproduced with permission from ref.[216]; 
Copyright 2018, Wiley-VCH. 
 
 
In another interesting example, Zhang et al. designed and fabricated an active pharmaceutical 
ingredient poly (ionic liquid) (API PIL)-based MN patches containing salicylic acid (SA) via 
photo-crosslinking of an imidazolium-type ionic liquid (IL) monomer in MN micro-molds, and 
following by anion exchange with SA
−
 anions [217]. Electrostatic interactions between 
imidazolium cation and SA anion facilitated loading salicylic acid anions onto PIL-MN. 
Characterization tests showed that the cross-linked SA-PIL-MN patches possessed high strength 
( > 0.72 MPa), high stretchability ( > 135 % strain), high compressibility ( > 60 % strain) and 
relatively high strength ( > 0.45 MPa) (Figure 18A and 18B). SEM images displayed that the 
bacteria (P. acnes and E. coli) were rod-like in control, and their surface remained smooth and 
complete, whereas culturing bacterial suspensions with the PIL-based MNs for 4 h resulted in 
irregular and unclear edges, atrophy, partial or complete membrane lysis or membrane 
perforation of the bacteria (Figure 18C). The SEM images further showed that the SA-PIL-MN 
patches had higher antimicrobial efficacy than only SA or only PIL-MN, mainly attributed to the 
synergistic activity of PIL and SA moieties against the bacteria. Histological and 
immunohistochemical analyses further demonstrated that expression of inflammatory cells and 













treated with SA-PIL-MN while only SA or only PIL-MN groups failed to exert noticeable anti-
inflammatory effects (Figure 18D and 18E).  
 
Figure 18. Anti-bacterial and anti-inflammatory effects of SA-loaded PIL-MNs in an acnes mice 
model. A) True tensile stress-strain. B) Compression stress-strain. C) SEM images showing P. 
acnes morphological changes in control, SA, PIL-MN, and SA- PIL-MNs for 4 h (scale bar: 1 
μm). D) H&E and immunohistochemical images displaying tissue damage and the expression of 
the TNF- α, IL-8, and MMP in P. acnes -infected skin 72 h post-operation in control, SA, PIL-
MN, and SA- PIL-MNs treated mice. Scale bar: 100 μm. E) The inflammatory cell counts and 
positive expression values of the TNF- α, IL-8, and MMP in control, SA, PIL-MN, and SA- PIL-
MNs groups.  Data are expressed as mean ± SD, (n = 3 per group); *P < 0.05, **P < 0.01. 
Reproduced with permission from ref. [217]; Copyright 2020, Elsevier B.V. 
 
 
8.3. MN design for atopic dermatitis treatment 
Atopic dermatitis (AD) is a common, chronic skin inflammatory disease that is characterized by 













about mechanisms of AD pathogenesis are not completely available, previous studies have 
shown that AD is associated with an overactive immune system, aggressive response to 
environmental irritants and allergens, and subsequently causing skin inflammation [219]. The 
onset and development of AD are associated with T helper type 2 (Th2)-polarized immune 
responses, including secretion of IL-4, IL-5, and IL-13 [220]. Excessive secretion of pro-
inflammatory cytokines creates a sequential chain of events, including stimulating 
immunoglobulin (Ig) E and IgG1 production by B cells, degranulation of mast cells, histamine 
release, and initiation of allergic responses [221, 222]. Chen et al. developed dissolvable MNs 
composed of low- and high- molecular-weight (LMW and HMW) poly- γ- glutamate ( γ-PGA) 
using micromolding method with immunomodulatory effects to effectively decrease abnormal 
immune responses and AD-like symptoms in Nc/Nga mice (Figure 19A) [223]. Their results 
demonstrated that γ-PGA MNs were able to penetrate the epidermis easily and modulate immune 
responses by releasing γ-PGA into the dendritic cell-rich dermis and its interaction with DCs. 
Compared to AD control, noticeable reductions of clinical dermatitis scores, epidermal thickness 
(Figure 19B), and mast cell infiltration (Figure 19C) in treated mice with γ-PGA MNs were 
found. The protective effects of engineered γ-PGA MNs were attributed to downregulation of 
IgE and IgG1 levels (Th2-associated antibodies) (Figure 19D-19F). There was no evidence of 
weight loss or abnormality in the MN-treated mice during the 8-week treatment period. 
Additionally, the authors found that the MW of γ-PGA highly affected immunomodulatory 














Figure 19. The γ-PGA MNs as transdermal immunomodulators for improving AD symptoms. A) 
Schematic representation of transdermal delivery of γ-PGA MNs for reducing skin inflammation 
through down-regulation of the IgE and IgG1 (Th2-associated antibodies) and hampering mast 
cell infiltration. PCL supporting substrate contributes to improving MN penetration by providing 
a greater length upon insertion, and then it can be quickly removed from the skin when the MN is 
dissolved within the skin. The dissolved γ-PGA directly confers DCs activation in the dermis, 
which in turn results in regulating immune responses towards ameliorating atopic dermatitis 
pathology. B) The epidermal thickness, and C) Mast cell number obtained from the H&E- and 
toluidine blue-stained skin sections at Week 8. D) Serum IgE, E) IgG1, and F) IgG2a. The serum 
levels were measured using ELISA. Data are expressed as the mean ± SD (n = 4 animals per 
group). *P < 0.05, **P < 0.01, ***P < 0.005 compared with the control group. Reproduced with 
permission from ref.[223]; Copyright 2020, Elsevier B.V. 
 
 
A recent study has shown the superiority of AD immunotherapy using MN technology compared 
to other routes of administration (IM, IP, oral, and SCIT). Kim et al. have evaluated the ability of 













coping with AD [224]. The researchers found that an antigen extract’s concentration of 10 µg 
into the MN patches created similar efficiency to subcutaneous immunotherapy with 100 µg of 
the antigen extract, as quantified by the improvement of clinical appearance and reduction of 
eosinophil cell counts, indicating that MN patches possess more substantial immunological 
efficacy and safety. Thereby, MN patches could be considered as potential candidates for the 
treatment of AD as they can transport antigen straightly into the epidermis and dermis at a lower 
dose, hence reducing the risk of anaphylaxis.  
 
8.4. MN for modulation of inflammation during the wound healing process 
Inflammation displays a powerful role during the wound healing process. In the first hours after 
injury, recruitment of inflammatory cells, and releasing different molecules by them contributes 
to matrix remodeling and keratinocyte migration towards promoting the healing process. After 
this initial response, which is mainly mediated by neutrophils, elimination of inflammation is 
essential to accelerate the healing process [225]. To this end, Jeon et al. developed a hydrogel-
forming double-layered adhesive MN patch comprising of a non-swellable SF-based core (for 
effective tissue fixation without delamination) and a swellable mussel adhesive protein (MAP)-
based shell that was able to improve wound sealing capacity through reduction of inflammatory 
responses [226]. In this system, in-situ rigid base was comprised of the regenerated SF with 
improved water solubility that was able to support effective tissue insertion of the adhesive MN 
patch. The hydrogel-forming adhesive MN patches exhibited good adhesion on wet and dynamic 
biological surfaces via both MAP-derived surface adhesive and swelling-mediated mechanical 
interlocking (Figure 20A). Monitoring time-dependent shape changes of various DL-MN patches 













the end of tip region while the base region of 80% DL-MN patches began to swell up due to high 
amounts of hydrophilic materials (Figure 20B). The authors reported the 80% DL-MN patch for 
surgical closure owing to detachment of the swollen shell from the core that hampered stable 
interfacial adhesion. A bud-like shaped MN structure was found for the 60% DL-MN patch at a 
maximum swollen state that provided the possibility of physical interlocking with surrounding 
tissues without delamination. In vivo experiments in a full-thickness incision of rat skin showed 
that the strip-type of 60% DL-MN patch showed excellent adhesion liquid absorption ability, 
which in turn resulted in good wound closure at days 4 and 7 compared to non-treatment and 
suture (Figure 20C and 20D). Histological examination with H&E-staining indicated that the 
60% DL-MN patch contributed to wound closure, re-epithelialization, and reducing 
inflammation and inflammatory cells into the wound site, whereas prolonged intense 
inflammation, delayed re-epithelialization, and impaired dermal healing over 21 days was seen 
for non-treatment group (Figure 20E). Masson’s Trichrome staining further confirmed fast 
deposition of produced collagen at the junction site and reducing inflammatory cells at days 4, 7, 
14, and 21 (Figure 20F). The ex vivo experiments demonstrated that hydrogel-forming adhesive 
MN patches had superior wound sealing capacity against luminal leaks (139.7 ± 14.1 mmHg) in 













Figure 20. The bioinspired adhesive MN patch for regenerative internal/external surgical closure 
by modulation of inflammation. A) Schematic representation for the proposed working 
mechanisms of a hydrogel-forming double-layered adhesive MN protein patch comprising of a 
non-swellable silk fibroin (SF)-based core (for effective tissue fixation without delamination) 













fluorescence and bright-field micrographs for investigation of time-dependent shape change of 
various DL-MN patches with different height ratios of the swellable MAP/HA layer after 
incubation in PBS at 0, 1, 5, and 10 min. White dashed circles show radial expansion by water 
absorption, and yellow triangles demonstrate the stiff core layer (scale bar=250 μm). C) 
Photographs of the transparent strip-type 60% DL-MN patch. Scale bar = 2 mm. D) Macroscopic 
photographs for wound healing of full-thickness incisions in rats following after non-treatment, 
suture treatment, and 60% DL-MN patch treatment at 0,4,7,14, and 21 days. E) H&E staining 
and F) Masson’s trichrome staining of skin wounds after non-treatment, suture treatment, and 
60% DL-MN patch treatment. Scabs are indicated as sc. Black arrows show inflammation, and 
black stars indicate defects. Scale bar = 500 μm. Reproduced with permission from ref.[226]; 
Copyright  2019 Elsevier B.V. 
 
 
In another interesting example, Gao et al. engineered an intelligent origami SF MN-structured 
dressing (i-SMD) with a smart drug release system and capability for epidermal sensing and 
wound healing (Figure 21A). The authors used temperature-responsive N-isopropylacrylamide 
(NIPAM) hydrogel and inverse opal (IO) photonic crystals (PCs) to obtain a controllable release 
of VEGF on the i-SMD. In order to improve the mechanical properties of SF membranes, the SF 
solution was mixed with PVA solution. Patterned SF-based MNs were fabricated using the 
micromolding technique. Microfluidic channels and electro circuits were first patterned on the 
same SF MN and then origami to prepare multifunctional integrated i-SMD. In vivo experiments 
showed that general wound closure rates were markedly higher in treated mice with VEGF i-
SMD than i-SMD and control (without treatment) groups (Figure 21B). Additionally, 
immunohistochemistry (IHC) staining showed that the secretion of inflammatory factors 
including IL-6 and TNF-α significantly reduced in VEGF i-SMD group compared to i-SMD and 














Figure 21. Intelligent SF based MNs dressing (i-SMD) for epidermal sensing and wound healing 
through modulation of inflammation. A) Schematic illustration of intelligent, biocompatible, 
stretchable, and highly integrated i-SMD for biochemical sensing and wound healing by 
modulation of inflammation. B) Representative images of wound closure rate in the diabetic 
mice treated with no therapy (control), blank i-SMD, and drug-loaded i-SMD (VEGF i-SMD). 
Scale bar = 1 cm. C) Immunohistochemistry staining of TNF-α and D) IL-6. The scale bar = 
100µm. Reproduced with permission from ref [227]; Copyright 2020, Wiley-VCH.  
 
10. Conclusions and future perspectives  
Although immunotherapy has been proposed as a clinical revolution, it still remains in its 
infancy. Detailed knowledge about its mechanistic intricacies is still not completely available, 
limiting the effective treatment of diseases in a safe, potent, and durable fashion by 
immunoengineering. In addition, the poor biodistribution of many immunotherapies can cause 













been made to design MN transdermal delivery systems to locally deliver immunotherapeutic 
with the highest efficiency and minimal invasiveness. Nevertheless, Concerns regarding the future 
success of MNs for clinical immunotherapy is totally dependent on FDA approval for novel 
biomaterials used in this delivery system for MN fabrication. In addition, future developments 
should take into account some of the current challenges, including the difficulty of precise 
coating of biomolecules on the MNs and insufficient delivery of therapeutic antigens, allergens, 
or immunotherapeutic drugs to the desired site.  
The improvement of the mechanical properties of MNs is another decisive factor for successful 
clinical translation and future commercialization. The mechanical characteristics of MN must 
meet two properties to ensure successful immunotherapy. First, the insertion force should be 
enough to neglect the skin friction force for the insertion of the MNs before puncturing the skin. 
Second, the insertion force must be higher than the skin force in order to perforate the skin and 
create holes in the epidermis/dermis layer. The insertion force strongly depends on thickness, the 
wall angle, and tip radius. Up to now, in vivo performance and efficiency of MN technology for 
immunotherapies have been mainly investigated on small animals, such as mice, rats, and 
rabbits, while the physiology, anatomy, and biomechanics of these animalsʼ skins are different 
from the human’s skin. Future evaluations of MN technology for immunotherapies should be 
implemented on the body of large animals (e.g., dogs and monkeys), on the excised human’s skin 
models, or even human volunteers. However, the skin properties of each person and even of 
various parts of the body are different; thereby additional investigation is required to determine 
the best application areas. Another concern regarding the wide clinical use of MNs is their large-
scale production in sterile conditions, which needs a carefully thought setting. The material type 













hollow and solid MNs fabricated by metals and silicon have mainly been applied in the clinical 
trial setup to deliver various immunotherapeutic molecules for immunotherapy, the lack of 
approval for silicon and the possibility of sharp hazardous tip wastes limit their clinical 
applications. Owing to the increasing interest in the design of biocompatible systems, researchers 
have recently focused on polymer science to fabricate biocompatible or dissolvable polymeric 
MNs with minimum side effects. Therefore, it is expected to see a tremendous interest in 
designing biocompatible and dissolvable MN systems in the near future with current advances in 
polymer science. We believe future researches should focus on the scaling up of sterile MNs 
with adequate loading capacity and minimal defects for clinical translation.  
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Table 1. A summary of various materials used into the structure of MNs towards 
immunotherapy, as well as a comparison of their advantages and limitations.  









Silicon Wet etch technology - Ability for coating of the 
viable virus in a dry form 
around the shaft of needles 












Silicon Wet etch technology - Successful delivery of 
liquid vaccinia virus Ankara 
(MVA) vaccine 





Silicon Wet etch technology Decreasing the anti-vector 
antibody response 
------ [39] 




al systems (MEMS) 
Easily fabrication using 
existing MEMS technologies 





 Silicon  
----- 
- Capability of surface 
decoration of  silicon with 
pH-sensitive groups towards 





antigen ( no for all 
the antigens) 
[41] 
 Silicon ------ ------ -Lack of FDA 


















penetration into the skin 
Possibility of 





           ---------- Capability for creating the 
nano-patterning on the 





agents owing to 
low hydrophilic 







Laser cutting Cost-effective and FDA 
approval for stainless MNs 













 Titanium Lithographic masking 
followed by wet 
etching 
Facile adsorption of 
Vaccine to the titanium 
surface via 
electrostatic/hydrophobic 
interactions due to high 
dielectric constant (ε ~ 114) 
and isoelectric point ( 
3.5–6.7) of titanium oxide 





Micromolding process Higher mechanical strength 
and better stability at high 
temperature and humidity 






















Micromolding process Capability for controlling 
drug release by changing the 
bulk surface area, porosity 
and resorbability of the 
ceramics 





Al2O3 Micromolding process Capability for creating 
nanoporous MNs for both 
delivery of substances, and 
the extraction of compounds 
---- [48] 









- Good in vivo resorbability 
(micromolding process) 
- Adjustable porosity 
Non-resorbability 
of sintered ceramic 
MNs 
[49] 
 Alumina - Sintering 
technique 

















Soft lithography Highly water solubility, high 
tensile strength, and FDA 
approval of PVP 
----- [51] 
 PVP Micromolding process  safely clearance of PVP via 
the kidneys within a few 
days 
---- [52] 
 PVP Micromolding process  Low likelihood of RNase 
contamination of PVP 
-Poor solubility of 
















- Inhibitory effect 
of concentrated 
PVP solutions on 
mRNA transfection 
due to steric 
hindrance. 
 PVP In situ micromolding 
process 
Good mechanical strength of 
PVP due to the presence of a 
ring in the chemical 
backbone structure of the 











 PVP/ dextran two-step molding 
process 
the adjuvant effects of PVP 
and dextran 
----- [55] 










into them during 
MN preparation 
[56] 
 chitosan Micromolding process - Excellent biodegradability 
- Noncytotoxicity 
- Ability of chitosan for 
improving both humoral and 
cell-mediated immune 
responses 
- creating  an antigen depot 










 Gantrez Micromolding process Highly water solubility and  










------- The difficulty of  
analysis of the 













 - FDA approval for both 
trehalose and CMC 
- Increasing antigen stability 
by trehalose 
- water-solubility and 














 CMC and 
amylopectin 




strength at high 






- Adjuvant properties of 
sodium alginate 
- Good biocompatibility 
and biodegradability 
- Utilizing  sodium alginate 








glycolic acid MN 
[63] 
 Silk fibroin 
/poly(acryli 
c acid) 
Micromolding process - Good 
Biocompatibility and 
Biodegradability of silk 
fibroin 
- Simple one-step process for 
loading antigens in silk 
protein matrices 
- Facile stabilization of 
immunotherapeutic agents 
and vaccines in silk at room 
temperature for more than 
two months 
- Rapid dissolution of PPA 
in the skin 
- Sustained vaccine release 
from silk protein matrices 
(over 1–2 weeks) 
- The high 








Micromolding process - Rapid dissolution of 
PPA in the skin 
- Adjustable sustained 
release of encapsulated 
vaccines based on the PLGA 
molecular weight 
- Complexity of 
the vaccine loading 








Dip-coating - Improving antigen stability 
during drying by trehalose 
disaccharide 
- Improving the retention of 
Hemagglutination activity of 
influenza vaccine after 
drying by trehalose 
Loss of 
Hemagglutination 
(HA) activity at 
high concentrations 






































Dip-coating Reducing virus aggregation 
at 3% concentration of 
trehalose 
Reduced delivery 
efficiency of the 





















Layer by layer 
assembly 
 
- Ability for the preparation 
of bioresponsive MNs due to 
photo-sensitive and pH-
responsive properties of 
PNMP polymer 
- Delivery of antigens in a 
sustained manner after 
photoswitching PNMP 
polymer through ultraviolet 




for 15 min during coating 





















 Microneedles are promising devices for painless drug delivery with high bioavailability. 
 Transdermal microneedle can improve the biological effect of drugs through adjustable drug 
release. 
 Facile fabrication and versatility have caused high attraction towards microneedle-based drug 
delivery. 
 Microneedles are suggested for immunotherapy due to the high abundance of immune cells 
under the skin. 
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